Datasets:

rahul77
/

LaTeX27

Modalities:

Image

Text

Formats:

Size:

Libraries:

Dataset card Data Studio Files Files and versions

xet

Community

Dataset Viewer

Auto-converted to Parquet Duplicate

Split (1)

train · 1k rows

image imagewidth (px) 230 933	latex stringlengths 184 5.27k	filename stringlengths 17 19
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Scale} & \multicolumn{4}{\|l\|}{\textbf{Self-report}} & \multicolumn{4}{\|l\|}{\textbf{Proxy-report}} \\ \hline & \textbf{N} & \textbf{Mean (sd)} & \textbf{df} & \textbf{F} & \textbf{N} & \textbf{Mean (sd)} & \textbf{df} & \textbf{F} \\ \hline Total Score & & & 4,1393 & 23.84 & & & 4,965 & 41.07 \\ \hline Asthma & 99 & 75.31(16.90) * & & & 74 & 71.79(17.53)* \\ \hline Diabetes & 124 & 82.46(12.76) & & & 103 & 77.54(12.21) * \\ \hline Cancer & 66 & 75.68(15.40) * & & & 61 & 70.96(17.06) * \\ \hline IBD & 76 & 74.18(14.66) * & & & 67 & 72.65(17.62) * \\ \hline Healthy & 1033 & 83.89(11.84) & & & 665 & 84.61(11.19) \\ \hline Physical Health & & & 4,1392 & 41.60 & & & 4,964 & 46.87 \\ \hline Asthma & 99 & 76.14(19.10)* & & & 75 & 73.36(20.60) * \\ \hline Diabetes & 124 & 84.75(13.65) & & & 103 & 82.97(13.67) * \\ \hline Cancer & 66 & 78.10(17.64) * & & & 61 & 75.04(18.79) * \\ \hline IBD & 76 & 75.08(18.21) * & & & 67 & 71.54(21.98) * \\ \hline Healthy & 1032 & 88.51(11.62) & & & 665 & 89.06(12.27) \\ \hline Psychosocial Health & & & 4,1393 & 14.53 & & & 4,964 & 28.16 \\ \hline Asthma & 99 & 74.9(17.48) * & & & 74 & 71.20(17.95) * \\ \hline Diabetes & 124 & 81.24(13.77) & & & 103 & 74.62(13.27) * \\ \hline Cancer & 66 & 74.37(15.85) * & & & 61 & 68.83(17.92) * \\ \hline IBD & 76 & 73.64(14.35) * & & & 67 & 73.21(17.43) * \\ \hline Healthy & 1033 & 81.84(13.21) & & & 664 & 82.21(12.67) \\ \hline Emotional functioning & & & 4,1393 & 9.85 & & & 4,962 & 23.24 \\ \hline Asthma & 99 & 70.66(20.06) * & & & 74 & 67.23(21.20) * \\ \hline Diabetes & 124 & 78.85(18.28) & & & 102 & 66.01(17.80) *** \\ \hline Cancer & 66 & 73.56(18.39) * & & & 61 & 68.36(18.04) * \\ \hline IBD & 76 & 68.11(18.90) * & & & 67 & 67.26(21.41) * \\ \hline Healthy & 1033 & 78.49(17.94) & & & 663 & 78.28(15.54) \\ \hline Social functioning & & & 4,1393 & 5.89 & & & 4,964 & 14.09 \\ \hline Asthma & 99 & 81.76(21.35) * & & & 74 & 76.96(21.69) * \\ \hline Diabetes & 124 & 89.15(13.91) & & & 103 & 85.28(15.98) \\ \hline Cancer & 66 & 81.27(18.36) & & & 61 & 73.28(22.93) *** \\ \hline IBD & 76 & 83.82(16.61) & & & 67 & 82.12(18.09) * \\ \hline Healthy & 1033 & 87.65(16.46) & & & 664 & 86.82(15.42) \\ \hline School functioning & & & 4,1386 & 14.12 & & & 4,960 & 26.90 \\ \hline Asthma & 99 & 72.37(19.62) * & & & 74 & 69.02(22.55) * \\ \hline Diabetes & 124 & 77.70(17.39) & & & 103 & 72.62(17.64) * \\ \hline Cancer & 63 & 67.38(20.36) * & & & 58 & 63.45(21.71) * \\ \hline IBD & 73 & 69.52(17.28) * & & & 66 & 70.46(20.95) *** \\ \hline Healthy & 1032 & 78.87(15.89) & & & 664 & 81.52(16.09) \\ \hline \end{tabular}} \end{table}	PMC1079918_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline \textbf{Functional type} & \textbf{Fluffy tails (F$>$2)} & \textbf{No fluffy tails (F$<$2)} & \textbf{Positive rate} & \textbf{Negative rate} \\ \hline Regulatory regions & 51 & 9 & 85 \% & 15 \% \\ \hline Exons & 1 & 59 & 1.6 \% & 98.4 \% \\ \hline Non-coding presumed non- regulatory & 10 & 50 & 16 \% & 84 \% \\ \hline \end{tabular}} \end{table}	PMC1127108_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline \textbf{Proliferation marker} & \textbf{rs} & \textbf{P} \\ \hline Thymidylate synthase & 0.38 & $<$0.001 \\ \hline Thymidine kinase 1 & 0.23 & $<$0.01 \\ \hline Survivin & 0.22 & $<$0.01 \\ \hline E2F & 0.22 & $<$0.01 \\ \hline Topoisomerase II$\alpha$ & 0.19 & $<$0.05 \\ \hline \end{tabular}} \end{table}	PMC1175052_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|} \hline \textbf{EM operation} & \textbf{Definition} \\ \hline Overlap (x ❍ y) & x and y overlap if they have a part in common. \\ \hline Disjoint (x ι y) & x and y are disjoint if they share no parts in common. \\ \hline Binary product (x . y) & The parts that x and y share in common. \\ \hline Difference (x - y) & The largest portion of x which has no part in common with y. \\ \hline Binary sum (x + y) & The set consisting of individuals x and y. \\ \hline \end{tabular}} \end{table}	PMC1175956_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|} \hline & \multicolumn{3}{\|l\|}{\textbf{Low A}} & \multicolumn{3}{\|l\|}{\textbf{Low B}} \\ \hline & \textbf{Observed} & \textbf{RR} & \textbf{p-value} & \textbf{Observed} & \textbf{RR} & \textbf{p-value} \\ \hline Not Adjusted & 440 & 0.81 & 0.004 & * & * & * \\ \hline Adjusted for Urban/Rural Status & 440 & 0.81 & 0.002 & * & * & * \\ \hline Adjusted for SES & * & * & * & 94 & 0.63 & 0.009 \\ \hline Adjusted for SES \& Urban/Rural Status & * & * & * & 94 & 0.635 & 0.016 \\ \hline \end{tabular}} \end{table}	PMC1180846_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline \textbf{Group} & \textbf{Patient Number} & \textbf{Follow up (months)} & \textbf{Raised IOP} & \textbf{Stepwise in last retinopathy FU (ETDRS) deterioration grade at} \\ \hline A & 1 & 15 & & 3 \\ \hline & & 14 & & 1 \\ \hline A & 2 & 6 & & 0 \\ \hline & & 8 & Yes: 34 mmHg & 0 \\ \hline A & 3 & 9 & & 0 \\ \hline A & 4 & 10 & & 0 \\ \hline & & 12 & Yes: 29 mm Hg & 1 \\ \hline A & 5 & 11 & Yes: 31 mm Hg & 0 \\ \hline A & 6 & 10 & & 1 \\ \hline & & 7 & & 0 \\ \hline A & 7 & 12 & & 0 \\ \hline A & 8 & 5 & Yes: 24 mmHg & 1 \\ \hline & & 5 & & 0 \\ \hline A & 9 & 7 & & 1 \\ \hline A & 10 & 6 & & 0 \\ \hline B & 10 & 4 & & 0 \\ \hline B & 11 & 8 & & 0 \\ \hline B & 12 & 4 & & 0 \\ \hline & & Mean FU = 8.5 \\ \hline \end{tabular}} \end{table}	PMC1183218_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Source} & \multicolumn{2}{\|l\|}{\textbf{dChip}} & \multicolumn{2}{\|l\|}{\textbf{MAS 5.0}} & \multicolumn{2}{\|l\|}{\textbf{RMA}} & \multicolumn{2}{\|l\|}{\textbf{GCRMA-EB}} \\ \hline & \textbf{Mean} & \textbf{SD} & \textbf{Mean} & \textbf{SD} & \textbf{Mean} & \textbf{SD} & \textbf{Mean} & \textbf{SD} \\ \hline Biological variation & 0.431 & 0.304 & 0.292 & 0.300 & 0.393 & 0.306 & 0.310 & 0.292 \\ \hline Labeling variation & 0.206 & 0.230 & 0.136 & 0.198 & 0.221 & 0.224 & 0.147 & 0.192 \\ \hline Residual error & 0.363 & 0.274 & 0.572 & 0.311 & 0.386 & 0.272 & 0.543 & 0.298 \\ \hline \end{tabular}} \end{table}	PMC1232851_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|} \hline & \textbf{Cont 3 M} & \textbf{Cont 6 M} & \textbf{Cont 11 M} & \textbf{Cont 21 M} & \textbf{Inulin 3 M} & \textbf{Inulin 6 M} & \textbf{Inulin 11 M} & \textbf{Inulin 21 M} & \textbf{inulin} & \textbf{age} & \textbf{interaction} \\ \hline Plasma Ca, mg/L & 98 $\pm$ 4 & 98 $\pm$ 5 & 95 $\pm$ 6 & 100 $\pm$ 5 & 102 $\pm$ 5 & 99 $\pm$ 4 & 98 $\pm$ 3 & 100 $\pm$ 4 & 0.0601 & 0.0619 & NS \\ \hline Tibia weight, mg dw & 480 $\pm$ 42 & 630 $\pm$ 80 & 717 $\pm$ 89 & 630 $\pm$ 93 & 489 $\pm$ 66 & 617 $\pm$ 66 & 841 $\pm$ 92 & 648 $\pm$ 47 & 0.042 & $<$0.0001 & 0.023 \\ \hline Bone Ca, mg/g dw & 207 $\pm$ 21 & 214 $\pm$ 15 & 216 $\pm$ 15 & 215 $\pm$ 21 & 205 $\pm$ 13 & 215 $\pm$ 18 & 202 $\pm$ 14 & 228 $\pm$ 7 & NS & 0.018 & 0.0639 \\ \hline Plasma Mg, mg/L & 17.9 $\pm$ 1.1 & 17.7 $\pm$ 1.1 & 17.2 $\pm$ 1.0 & 16.9 $\pm$ 1.3 & 17.6 $\pm$ 1.1 & 17.9 $\pm$ 1.3 & 18.2 $\pm$ 1.5 & 18.2 $\pm$ 1.7 & 0.0570 & NS & NS \\ \hline Erythrocyte Mg, mg/L & 45.4 $\pm$ 3.8 & 44.2 $\pm$ 4.7 & 42.5 $\pm$ 3.4 & 43.4 $\pm$ 3.0 & 44.9 $\pm$ 4.9 & 43.8 $\pm$ 2.5 & 44.3 $\pm$ 3.6 & 43.8 $\pm$ 3.9 & NS & NS & NS \\ \hline Bone Mg, mg/g dw & 3.92 $\pm$ 0.10 & 3.79 $\pm$ 0.08 & 3.72 $\pm$ 0.08 & 3.76 $\pm$ 0.08 & 3.91 $\pm$ 0.10 & 3.72 $\pm$ 0.07 & 3.73 $\pm$ 0.09 & 3.72 $\pm$ 0.09 & NS & $<$0.0001 & NS \\ \hline \end{tabular}} \end{table}	PMC1283151_table_4
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline \textbf{Type of post consultation letter} & \textbf{Letter to General Practitioner} & \textbf{Letter to patient} & \textbf{Significance (Wilcoxin Signed Ranks test)} \\ \hline Length (minutes of $\pm$ time SD, to n) dictate letter & 3.28 $\pm$ 2.2, 81 & 2.57 $\pm$ 1.42, 82 & p = 0.019 \\ \hline Flesch Reading Ease Score & 49.76 $\pm$ 9.1, 84 & 55.44 $\pm$ 9.26, 84 & p $<$ 0.001 \\ \hline Flesch-Kincaid Grade Level & 10.72 $\pm$ 1.43 & 11.04 $\pm$ 1.39 & p = 0.062 \\ \hline Circled items in each letter & 31/63 circled 1–12 items & 16/63 circled 1–5 items & p $<$ 0.001 \\ \hline Word Count & 444 $\pm$ 169.87 & 351.5 $\pm$ 129.05 & p $<$ 0.001 \\ \hline \end{tabular}} \end{table}	PMC1360088_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|l\|l\|} \hline & \multicolumn{2}{\|l\|}{\textbf{dvSalt30}} & \multicolumn{2}{\|l\|}{\textbf{ecox}} & \multicolumn{2}{\|l\|}{\textbf{shHeat5}} & \multicolumn{2}{\|l\|}{\textbf{shCold5}} \\ \hline \textbf{Method} & \textbf{\#Genes} & \textbf{\%Agree} & \textbf{\#Genes} & \textbf{\%Agree} & \textbf{\#Genes} & \textbf{\%Agree} & \textbf{\#Genes} & \textbf{\%Agree} \\ \hline 1-gene (OpWise) & 220 & 100\% & 1062 & 98\% & 1002 & 97\% & 187 & 100\% \\ \hline operon-wise & 401 & 99\% & 1318 & 100\% & 1284 & 99\% & 374 & 100\% \\ \hline no-bias & 1090 & 90\% & 1269 & 98\% & 3020 & 87\% & 3063 & 70\% \\ \hline SAM & 852 & 94\% & 957 & 99\% & 3348 & 83\% & 3258 & 68\% \\ \hline \end{tabular}} \end{table}	PMC1397872_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{AAA model} & \textbf{P (mmHg)} & \textbf{dAAA,max (cm)} & \textbf{Thickness (cm) t} & \textbf{$\alpha$} & \textbf{$\beta$} & \textbf{(Authors' results) Stress (MPa)} & \multicolumn{2}{\|l\|}{\textbf{Modified Equation Laplace}} & \multicolumn{2}{\|l\|}{\textbf{Original Equation Laplace}} \\ \hline & & & & & & & \textbf{Stress (MPa)} & \textbf{Error} & \textbf{Stress (MPa)} & \textbf{Error} \\ \hline Fillinger [3,4] & 120 & 6.7 & 0.19 & 0 & 0.4 & 0.32 & 0.34 & 6.3\% & 0.28 & 13\% \\ \hline & 130 & 5.5 & 0.19 & 0 & 0.4 & 0.30 & 0.28 & 6.7\% & 0.25 & 16.7\% \\ \hline Wang [29] & 128 & 6.1 & 0.184 & 0.54 & 0.33 & 0.19 & 0.208 & 9.5\% & 0.28 & 47\% \\ \hline & 155 & 6.4 & 0.175 & 0.29 & 0.9 & 0.35 & 0.34 & 2.9\% & 0.38 & 8.6\% \\ \hline Vorp [36] & 120 & 6.0 & 0.15 & 0 & 0.3 & 0.33 & 0.34 & 3\% & 0.31 & 6\% \\ \hline Raghavan [45] & 115 & 5.2 & 0.19 & 0 & 0.65 & 0.23 & 0.21 & 8.7\% & 0.2 & 13\% \\ \hline & 188 & 5.5 & 0.19 & 0 & 0.9 & 0.43 & 0.46 & 6.9\% & 0.36 & 16\% \\ \hline Thubrikar [15] & 120 & 5.86 & 0.104 & 0 & 0.5 & 0.37 & 0.39 & 5.4\% & 0.45 & 22\% \\ \hline & 120 & 5.86 & 0.158 & 0 & 0.5 & 0.3 & 0.299 & 0.3\% & 0.29 & 3.3\% \\ \hline Li [44] & 120 & 5.0 & 0.05 & 0.15 & 1 & 0.43 & 0.41 & 4.6\% & 0.80 & 85.6\% \\ \hline \end{tabular}} \end{table}	PMC1421417_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline \textbf{Effect Size} & \textbf{Failure Rate 95\%} & \textbf{Failure Rate 98\%} \\ \hline 30\% & 235 & 195 \\ \hline 33.3\% & 185 & 160 \\ \hline 35\% & 160 & 140 \\ \hline 40\% & 120 & 95 \\ \hline \end{tabular}} \end{table}	PMC1459124_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Source} & \textbf{DF} & \multicolumn{5}{\|l\|}{\textbf{F value}} \\ \hline & & \textbf{Critical} & \textbf{Dorsal vein} & \textbf{Caudal vein} & \textbf{Dorsal artery} & \textbf{Caudal artery} \\ \hline Family & 3 & 2.91 & 11.35* & 1.35 & 8.74* & 0.58 \\ \hline Environment & 1 & 4.16 & 1.87 & 3.70 & 12.10* & 7.71* \\ \hline Family Environment $\times$ & 3 & 2.91 & 0.30 & 0.30 & 2.11 & 0.46 \\ \hline Error & 38 \\ \hline \end{tabular}} \end{table}	PMC1479343_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|} \hline \textbf{Compound (µg/ml)} & \textbf{IL-8 released (pg/ml)} \\ \hline Medium alone & 24.6 $\pm$ 1.5 \\ \hline Tryptase 2.0 & 105.2 $\pm$ 5.3* \\ \hline Elastase 0.3 & 108.4 $\pm$ 13.2* \\ \hline Benzamidine 30 & 37.6 $\pm$ 4.4 \\ \hline Leupeptine 30 & 27.4 $\pm$ 5.6 \\ \hline MSACK 30 & 22.1 $\pm$ 4.3 \\ \hline Tryptase 2.0 + Benzamidine 30 & 66.9 $\pm$ 4.8† \\ \hline Tryptase 2.0 + Leupeptin 30 & 100 $\pm$ 1.7 \\ \hline Elastase 0.3 + MSACK 30 & 26.9 $\pm$ 3.6† \\ \hline \end{tabular}} \end{table}	PMC1489934_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline \textbf{Variable} & \multicolumn{2}{\|l\|}{\textbf{Unemployment Duration (\%/n)}} & \textbf{t (p)} \\ \hline & \textbf{Short-term N = 234} & \textbf{Long-term N = 195} \\ \hline \multicolumn{4}{\|l\|}{Depression months) (in past 12} \\ \hline Never & 15.8/37 & 16.4/32 & 0.17 (sn) \\ \hline Sometimes & 50.4/118 & 32.8/64 & 3.75 (p $<$ 0.001) \\ \hline Often & 29.5/69 & 39.5/77 & 2.17 (p $<$ 0.05) \\ \hline Always & 4.3/10 & 11.3/22 & 2.67 (p $<$ 0.01) \\ \hline \multicolumn{4}{\|l\|}{Depression unemployment) (after} \\ \hline Do not feel at all & 14.1/33 & 11.8/23 & 0.71 (sn) \\ \hline No significant changes & 43.2/101 & 33.8/66 & 2.01 (p $<$ 0.05) \\ \hline Feel more often & 39.7/93 & 51.8/101 & 2.52 (p $<$ 0.05) \\ \hline Feel less & 3.0/7 & 2.6/5 & 0.25 (sn) \\ \hline \multicolumn{4}{\|l\|}{Use of sedative drugs} \\ \hline At least once in the last 30 days & 19.2/45 & 25.6/50 & 1.58 (sn) \\ \hline \end{tabular}} \end{table}	PMC1526724_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Year} & \textbf{Estimated population\#} & \textbf{Birth cohort} & \textbf{Vaccination coverage} & \textbf{Vaccine efficacy*} & \textbf{Children susceptible} & \textbf{Cumulated population susceptible} \\ \hline 1988 & 2,076,264 & 44,432 & 103.19\% & 85\% & 5,459 & 5,459 \\ \hline 1989 & 2,091,648 & 46,853 & 105.50\% & 85\% & 4,837 & 10,296 \\ \hline 1990 & 2,107,146 & 44,461 & 101.67\% & 85\% & 6,038 & 16,334 \\ \hline 1991 & 2,122,759 & 44,153 & 100.65\% & 85\% & 6,378 & 22,712 \\ \hline 1992 & 2,138,488 & 44,267 & 104.57\% & 85\% & 4,921 & 27,633 \\ \hline 1993 & 2,154,333 & 42,009 & 102.70\% & 85\% & 5,337 & 32,970 \\ \hline 1994 & 2,170,295 & 41,670 & 102.51\% & 85\% & 5,362 & 38,332 \\ \hline 1995 & 2,186,376 & 44,383 & 104.92\% & 85\% & 4,803 & 43,135 \\ \hline 1996 & 2,202,576 & 42,289 & 101.57\% & 85\% & 5,779 & 48,913 \\ \hline 1997 & 2,218,896 & 42,603 & 100.74\% & 85\% & 6,124 & 55,037 \\ \hline 1998 & 2,235,337 & 42,918 & 99.28\% & 85\% & 6,700 & 61,737 \\ \hline 1999 & 2,251,900 & 43,462 & 101.25\% & 85\% & 6,058 & 67,795 \\ \hline 2000 & 2,268,586 & 43,784 & 101.13\% & 85\% & 6,148 & 73,944 \\ \hline 2001 & 2,285,395 & 44,108 & 105.18\% & 85\% & 4,674 & 78,617 \\ \hline 2002 & 2,302,329 & 44,435 & 102.56\% & 85\% & 5,697 & 84,314 \\ \hline 2003 & 2,319,388 & 44,764 & 101.46\% & 85\% & 6,159 & 90,473 \\ \hline 2004 & 2,336,574 & 45,096 & 99.57\% & 85\% & 6,928 & 97,401 \\ \hline \end{tabular}} \end{table}	PMC1586205_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|} \hline Class & \multicolumn{14}{\|l\|}{3 1065 [336]} \\ \hline Subclass & 3.1 [113] 267 & \multicolumn{2}{\|l\|}{3.2 163 [56]} & 3.3 [4] 10 & 3.4 [49] 317 & 3.5 [70] 171 & 3.6 [36] 109 & 3.7 [4] 10 & 3.8 [1] 10 & 3.9 [1] 1 & 3.10 [1] 2 & 3.11 [0] 2 & 3.12 [1] 1 & 3.13 [0] 2 \\ \hline subclass Sub- & & 3.2.1 [45] 140 & 3.2.2 [11] 23 \\ \hline \end{tabular}} \end{table}	PMC1609188_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Authors} & \textbf{No. of Subjects} & \textbf{Test} & \textbf{Sensitivity (\%)} & \textbf{Specificity (\%)} & \textbf{QUADAS Score} \\ \hline Thomas et al [24] & 297 & Kernig & 5* & 95* \\ \hline & & & 9 & 96 & 7 \\ \hline & & & 0* & 95* \\ \hline & & Brudzinski & 5* & 95* \\ \hline & & & 9 & 96 \\ \hline & & & 25 & 96 \\ \hline \end{tabular}} \end{table}	PMC1635718_table_7
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Village} & \textbf{Paddy category} & \textbf{No. of Habitats} & \textbf{1stinstars} & \textbf{2nd instars} & \textbf{3rd instars} & \textbf{4th instars} & \textbf{Pupae} \\ \hline Kangichiri & Ploughed & 25 & 1.41 & 0.95 & 0.09 & 0.00 & 0.36 \\ \hline & Flooded & 23 & 1.67 & 1.10 & 0.30 & 0.00 & 0.36 \\ \hline & Post transplanting & 30 & 6.02 & 3.00 & 1.89 & 1.20 & 0.99 \\ \hline & Tillering & 28 & 8.00 & 6.67 & 2.00 & 3.22 & 0.67 \\ \hline & Flowering/ maturation & 27 & 0.01 & 0.00 & 0.02 & 0.01 & 0.00 \\ \hline & Fallow & 27 & 1.00 & 0.67 & 0.00 & 0.00 & 0.01 \\ \hline Kiuria & Ploughed & 22 & 0.00 & 0.00 & 0.00 & 0.00 & 0.00 \\ \hline & Flooded & 23 & 1.23 & 0.65 & 0.07 & 0.01 & 0.0 \\ \hline & Post transplanting & 21 & 5.58 & 1.63 & 0.17 & 0.51 & 0.19 \\ \hline & Tillering & 22 & 8.50 & 5.25 & 0.25 & 0.25 & 1.25 \\ \hline & Flowering/ maturation & 20 & 0.02 & 0.00 & 0.01 & 0.0 & 0.00 \\ \hline & Fallow & 14 & 0.03 & 0.01 & 0.0 & 0.01 & 0.00 \\ \hline Rurumi & Ploughed & 18 & 0.00 & 0.00 & 0.00 & 0.00 & 0.00 \\ \hline & Flooded & 21 & 1.56 & 1.28 & 0.09 & 0.06 & 0.19 \\ \hline & Post transplanting & 20 & 5.73 & 3.37 & 1.17 & 1.03 & 0.47 \\ \hline & Tillering & 20 & 4.91 & 4.67 & 1.19 & 1.11 & 1.00 \\ \hline & Flowering/ maturation & 15 & 0.00 & 0.00 & 0.00 & 0.00 & 0.00 \\ \hline & Fallow & 12 & 1.17 & 0.00 & 0.00 & 0.00 & 0.00 \\ \hline \end{tabular}} \end{table}	PMC1636646_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline & \multicolumn{2}{\|l\|}{\textbf{Respondents}} & \multicolumn{2}{\|l\|}{\textbf{Dropouts}} \\ \hline \textbf{Characteristics at baseline} & \textbf{N} & \textbf{\%} & \textbf{N} & \textbf{\%} \\ \hline \multicolumn{5}{\|l\|}{Age (years)} \\ \hline $<$ 30 & 273 & 6.7 & 137 & 13.7 \\ \hline 30–39 & 824 & 20.2 & 221 & 22.1 \\ \hline 40–49 & 1778 & 43.6 & 338 & 33.8 \\ \hline 50–59 & 1065 & 26.1 & 265 & 26.5 \\ \hline $>$ 59 & 136 & 3.3 & 39 & 3.9 \\ \hline \multicolumn{5}{\|l\|}{Gender} \\ \hline Female & 3912 & 96.0 & 947 & 94.9 \\ \hline Male & 164 & 4.0 & 51 & 5.1 \\ \hline \multicolumn{5}{\|l\|}{Marital status} \\ \hline Married or cohabiting & 3271 & 80.3 & 771 & 77.3 \\ \hline Single & 800 & 19.7 & 227 & 22.7 \\ \hline \multicolumn{5}{\|l\|}{Have preschool children} \\ \hline No & 3490 & 87.0 & 843 & 85.8 \\ \hline Yes & 522 & 13.0 & 140 & 14.2 \\ \hline \multicolumn{5}{\|l\|}{Special tasks of care taking during leisure time †} \\ \hline No & 2944 & 72.6 & 721 & 72.6 \\ \hline Yes & 1112 & 27.4 & 272 & 27.4 \\ \hline \multicolumn{5}{\|l\|}{Pregnant} \\ \hline No & 3978 & 99.1 & 955 & 98.0 \\ \hline Yes & 37 & 0.9 & 19 & 2.0 \\ \hline \multicolumn{5}{\|l\|}{Long-term health problems (any kind)} \\ \hline No or "yes, but not bothered" & 3006 & 74.4 & 736 & 74.4 \\ \hline Yes, and bothered by it & 1033 & 25.6 & 253 & 25.6 \\ \hline \multicolumn{5}{\|l\|}{Regular physical exercise} \\ \hline No & 1724 & 42.4 & 451 & 45.2 \\ \hline Yes & 2343 & 57.6 & 547 & 54.8 \\ \hline \multicolumn{5}{\|l\|}{Years of experience as nurses' aide} \\ \hline $<$ 10 years & 706 & 17.3 & 235 & 23.5 \\ \hline 10 years or more & 3370 & 82.7 & 764 & 76.5 \\ \hline \end{tabular}} \end{table}	PMC1693921_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline \textbf{CDS} & \textbf{Gene name} & \textbf{Predicted function} & \textbf{m-value RES167} & \textbf{m-value CL1} \\ \hline \multicolumn{5}{\|l\|}{BIOTIN BIOSYNTHESIS AND TRANSPORT} \\ \hline cg0095 & bioB & biotin synthase & 3.69 & 1.55 \\ \hline cg2147 & bioY & membrane protein, BioY family & 3.70 & 1.51 \\ \hline cg2148 & & ABC transporter, ATP-binding protein & 3.11 & 1.51 \\ \hline cg2149 & & permease (cobalt permease subfamily) & 1.63 & 0.75* \\ \hline cg2885 & bioA & adenosylmethionine-8-amino-7-oxononanoate aminotransferase & 2.09 & 0.91* \\ \hline cg2886 & bioD & dethiobiotin synthetase protein & 1.32 & 0.76* \\ \hline cg1227 & & ABC-type cobalt transport system & 1.58 & 1.48 \\ \hline \multicolumn{5}{\|l\|}{FUNCTION UNKNOWN} \\ \hline cg0378 & & putative phage-associated protein & 1.14 & 1.61 \\ \hline \multicolumn{5}{\|l\|}{SULFONATE (ESTER) METABOLISM AND TRANSPORT} \\ \hline cg1147 & ssuI & reductase involved in sulfonate degradation & -1.25 & -1.70 \\ \hline cg1152 & seuB & sulfonate ester monoxygenase & -1.35 & -1.25 \\ \hline cg1153 & seuC & sulfonate ester monooxygenase & -0.99* & -1.07 \\ \hline cg1156 & ssuD2 & alkanesulfonate monooxygenase & -2.23 & -1.00 \\ \hline cg1376 & ssuD1 & alkanesulfonate monooxygenase & -2.11 & -1.61 \\ \hline cg1377 & ssuC & aliphatic sulfonates ABC transporter & -2.17 & -1.32 \\ \hline cg1379 & ssuB & aliphatic sulfonates ABC transporter & -1.75 & -0.74* \\ \hline \multicolumn{5}{\|l\|}{CELL DIVISION} \\ \hline cg2378 & mraZ & MraZ protein & -1.02 & -1.16 \\ \hline \end{tabular}} \end{table}	PMC1779776_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline \textbf{Accession no} & \textbf{Symbol} & \textbf{Gene Name} & \textbf{Reference} \\ \hline \multicolumn{4}{\|l\|}{Chemokines and receptors} \\ \hline [genebank:NM_002983] & CCL3 & Chemokine, CC motif, Ligand 3 $\pi$ & [25] \\ \hline [genebank:NM_002984] & CCL4 & Chemokine, CC motif, ligand 4 $\pi$ & [25] \\ \hline [genebank:NM_005408] & CCL13 & Chemokine, CC motif, ligand 13 & [68] \\ \hline [genebank:NM_032964] & CCL15 & Chemokine, CC motif, ligand 15 & [69] \\ \hline [genebank:NM_006274] & CCL19 & Chemokine, CC motif, ligand 19 & -1748* \\ \hline [genebank:NM_002990] & CCL22 & Chemokine, CC motif, ligand 22 $\pi$ & [70] \\ \hline [genebank:NM_001511] & CXCL1 & Chemokine CC motif, Ligand 1 $\pi$ & [25] \\ \hline [genebank:NM_002089] & CXCL2 & Chemokine, CXC motif, ligand 2 $\pi$ & [25] \\ \hline [genebank:NM_000584] & CXCL8 & Chemokine, CXC motif, ligand 8 $\pi$ & [25] \\ \hline [genebank:NM_001565] & CXCL10 & Chemokine, CXC motif, ligand 10 & [25] \\ \hline [genebank:NM_005408] & CXCL13 & Chemokine, CXC motif, ligand 13 & -1593* \\ \hline [genebank:U28934] & CCR2 & Chemokine, CC motif, receptor 2 & -1543* \\ \hline [genebank:NM_003467] & CXCR4 & Chemokine, CXC motif, receptor 4 $\pi$ & [71] \\ \hline \multicolumn{4}{\|l\|}{Cytokines and Receptors} \\ \hline [genebank:NM_000594] & TNF-$\alpha$ & Tumour Necrosis Factor $\alpha$ $\pi$ & [25] \\ \hline [genebank:NM_000576] & IL1-$\beta$ & Interleukin 1 B $\pi$ & [25] \\ \hline [genebank:NM_000577] & IL1-RN & Interleukin 1 receptor antagonist $\pi$ & [25] \\ \hline [genebank:NM_005746] & PBEF & Pre B cell colony stimulating factor 1 $\pi$ & -533, -479 \\ \hline [genebank:NM_001250] & TNFRSF5 & TNF receptor superfamily, member 5 & [72] \\ \hline [genebank:NM_001561] & TNFRSF9 & TNF receptor superfamily member 9 & [73] \\ \hline [genebank:NM_005534] & IFNGR2 & Interferon, gamma receptor 2 & -317, -220, -144, -134 \\ \hline \multicolumn{4}{\|l\|}{Stress} \\ \hline [genebank:NM_000636] & SOD2 & Superoxide dismutase 2 $\pi$p & [25] \\ \hline [genebank:NM_000963] & COX2 & Cycloxygenase 2 $\pi$ & [25] \\ \hline [genebank:NM_006427] & TXNIP & Thioredoxin interacting protein $\pi$ & -618 \\ \hline \multicolumn{4}{\|l\|}{Apoptosis} \\ \hline [genebank:NM_015675] & GADD45 $\beta$ & Growth arrest and DNA damage inducible gene GADD45, B $\pi$ & [74] \\ \hline [genebank:NM_005879] & TRIP & Traf interacting protein & -1736 \\ \hline [genebank:NM_006290] & TNFAIP3 & Tumour Necrosis factor $\alpha$ induced protein 3 $\pi$ & [25] \\ \hline [genebank:NM_001165] & cIAP2 & Cellular inhibitor of apoptosis 2 $\pi$ & [75] \\ \hline \multicolumn{4}{\|l\|}{Transcription} \\ \hline [genebank:NM_020529] & I$\kappa$B-$\alpha$ & Inhibitor of $\kappa$light chain gene enhancer in B cells; $\alpha$ $\pi$ & [25] \\ \hline [genebank:NM_003998] & NF$\kappa$B1 & Nuclear factor of $\kappa$B, subunit 1 $\pi$ & [25] \\ \hline [genebank:NM_002908] & C-REL & V-rel avain reticuloendotheliosis viral oncogene homolog; rel $\pi$ & [25] \\ \hline [genebank:NM_005375] & C-MYB & V-MYB avian myeloblastosis viral oncogene homolog $\pi$ & [25] \\ \hline [genebank:NM_004364] & CEBP$\alpha$ & CAAT/enhancer binding protein $\alpha$ & [25] \\ \hline [genebank:U96131] & TRIP13 & Thyroid hormone interactor 13 & -1611, -1601, -1600 -1464* \\ \hline [genebank:NM_002129] & HMGB2 & High mobility group box 2 & -1531, -1520, -1087 \\ \hline \multicolumn{4}{\|l\|}{Cell Cycle/Differentiation} \\ \hline [genebank:NM_006763] & BTG2 & B-cell translocation gene 2 $\pi$ & [76] \\ \hline [genebank:NM_002166] & ID2 & Inhibitor of DNA binding 2 $\pi$ & -571, -174 \\ \hline [genebank:X54941] & CKS1B & CDC28 protein kinase 1B & -1416, -1406 -717, -647, -637, -646 -636 \\ \hline [genebank:NM_004701] & CCNB2 & Cyclin B2 & -1387 \\ \hline \multicolumn{4}{\|l\|}{Growth} \\ \hline [genebank:NM_000598] & IGFBP3 & Insulin-like growth-factor binding protein 3 $\pi$ & -1729 \\ \hline \multicolumn{4}{\|l\|}{Miscellaneous} \\ \hline [genebank:NM_000674] & ADORA1 & Adenosine A1 receptor & [25] \\ \hline [genebank:NM_000201] & ICAM1 & Intracellular adhesion molecule 1 $\pi$ & [25] \\ \hline [genebank:NM_002421] & MMP1 & Matrix metalloproteinase 1 & [25] \\ \hline [genebank:X13895] & SAA3P & Serum amyloid A3 pseudogene & -1790* \\ \hline [genebank:NM_002291] & LAM$\beta$1 & Laminin, $\beta$ 1 & -263, -253 \\ \hline [genebank:NM_004119] & FLT3 & FMS related tyrosine kinase 3 & -295, -285* \\ \hline [genebank:NM_001365] & DLG4 & Discs, large homolog 4 & -1425, -1415, -544 \\ \hline [genebank:M22001] & F13A1 & Coagulation factor X111, A1 polypeptide & -404, -72* \\ \hline \end{tabular}} \end{table}	PMC1781469_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|} \hline \textbf{Scoliosis} & \textbf{Karyotype} \\ \hline 12° Right thoracic, hypokyphosis & 45XO \\ \hline 30° Right Thoraco-lumbar & 45XO \\ \hline 18° Right thoracic, hypokyphosis & 46XisoX(q10) Mosaic \\ \hline 30° Right Thoraco-lumbar & 45XO \\ \hline No Xrays Mild clinical deformity Right thoracic & 45XO \\ \hline 17° Left Thoraco-lumbar & 45XO \\ \hline 18° Right thoracic, hypokyphosis & 45XO \\ \hline 55° Right thoracic Scoliosis surgery & 45XO \\ \hline 45° Right thoracic, hypokyphosis & 45XO \\ \hline 10° Right lumbar & Diagnosed South Africa. Karyotype not available. \\ \hline 20° Left Thoraco-lumbar & 45XO \\ \hline 12° left Thoraco-lumbar & 45XO/46XY mosaic Undiagnosed syndrome \\ \hline 45° Right Thoracic, hypokyphosis & 45XO \\ \hline \end{tabular}} \end{table}	PMC1808441_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{$\delta$} & \textbf{C1} & \textbf{C2} & \textbf{C3} & \textbf{C4} & \textbf{C5} & \textbf{C6} & \textbf{C7} & \textbf{C8} & \textbf{C9} & \textbf{C} & \textbf{V} & \textbf{V1} & \textbf{V2} & \textbf{V3} & \textbf{V4} & \textbf{V5} & \textbf{V6} & \textbf{V7} & \textbf{V8} \\ \hline C1 & 0 & 4.40 & 5.08 & 4.63 & 4.65 & 5.08 & 4.26 & 4.70 & 3.52 & 2.55 & 3.70 & 3.62 & 2.80 & 3.67 & 3.77 & 3.37 & 3.70 & 4.00 & 3.25 \\ \hline C2 & & 0 & 6.25 & 5.77 & 5.93 & 6.38 & 5.90 & 4.65 & 5.37 & 2.58 & 4.60 & 4.46 & 3.47 & 4.53 & 4.72 & 4.96 & 4.94 & 4.72 & 3.78 \\ \hline C3 & & & 0 & 6.00 & 6.62 & 5.69 & 5.77 & 5.35 & 5.35 & 2.85 & 4.86 & 4.78 & 4.07 & 4.51 & 4.71 & 4.87 & 5.18 & 4.76 & 4.73 \\ \hline C4 & & & & 0 & 6.36 & 5.71 & 5.22 & 5.06 & 5.09 & 2.65 & 4.95 & 4.70 & 3.48 & 4.85 & 5.14 & 5.04 & 4.13 & 5.26 & 4.28 \\ \hline C5 & & & & & 0 & 6.86 & 6.08 & 6.17 & 5.00 & 2.97 & 4.88 & 4.81 & 3.64 & 4.96 & 5.35 & 4.95 & 5.41 & 4.71 & 4.54 \\ \hline C6 & & & & & & 0 & 6.21 & 4.70 & 5.25 & 3.18 & 4.70 & 4.60 & 3.40 & 4.75 & 4.74 & 4.75 & 4.67 & 5.20 & 3.90 \\ \hline C7 & & & & & & & 0 & 4.92 & 4.85 & 2.37 & 4.71 & 5.15 & 3.93 & 5.16 & 4.99 & 4.93 & 4.63 & 4.47 & 4.88 \\ \hline C8 & & & & & & & & 0 & 4.34 & 2.66 & 4.68 & 3.77 & 3.20 & 4.25 & 4.11 & 4.80 & 4.04 & 4.50 & 3.36 \\ \hline C9 & & & & & & & & & 0 & 2.48 & 3.84 & 3.92 & 3.22 & 4.16 & 4.32 & 4.13 & 4.84 & 4.00 & 3.32 \\ \hline C & & & & & & & & & & 0 & 3.35 & 3.64 & 3.19 & 3.70 & 3.78 & 3.62 & 3.99 & 2.96 & 3.01 \\ \hline V & & & & & & & & & & & 0 & 2.25 & 2.07 & 1.91 & 2.11 & 2.09 & 2.21 & 1.87 & 2.36 \\ \hline V1 & & & & & & & & & & & & 0 & 2.41 & 3.79 & 3.26 & 3.07 & 3.59 & 3.64 & 3.57 \\ \hline V2 & & & & & & & & & & & & & 0 & 2.79 & 2.73 & 2.71 & 2.59 & 2.77 & 2.34 \\ \hline V3 & & & & & & & & & & & & & & 0 & 3.63 & 3.77 & 3.60 & 4.54 & 3.41 \\ \hline V4 & & & & & & & & & & & & & & & 0 & 3.57 & 3.66 & 4.09 & 4.03 \\ \hline V5 & & & & & & & & & & & & & & & & 0 & 4.08 & 3.77 & 3.69 \\ \hline V6 & & & & & & & & & & & & & & & & & 0 & 4.25 & 3.52 \\ \hline V7 & & & & & & & & & & & & & & & & & & 0 & 3.83 \\ \hline V8 & & & & & & & & & & & & & & & & & & & 0 \\ \hline \end{tabular}} \end{table}	PMC1847453_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline \textbf{Patient characteristics} & \multicolumn{3}{\|l\|}{\textbf{Group}} & \textbf{P-value} \\ \hline & \textbf{Faculty physician (\%)} & \textbf{General doctor (\%)} & \textbf{Resident (\%)} \\ \hline Mean age (SD), years & 50.39 (15.65) & 49.32 (15.86) & 49.55 (15.39) & 0.07 \\ \hline \multicolumn{5}{\|l\|}{Sex} \\ \hline Male & 233 (30.50) & 92 (24.90) & 249 (31.50) & 0.07 \\ \hline Female & 530 (69.50) & 277 (75.10) & 542 (68.50) \\ \hline \multicolumn{5}{\|l\|}{Status of patients} \\ \hline New patients & 113 (14.50) & 75 (16.40) & 235 (36.70) & 0.00 \\ \hline Existing patients & 665 (85.50) & 382 (83.60) & 405 (63.30) \\ \hline \multicolumn{5}{\|l\|}{Funding of patient} \\ \hline Universal coverage & 37 (4.70) & 8 (1.80) & 30 (4.70) & 0.10 \\ \hline Social welfare & 62 (7.90) & 38 (8.40) & 38 (5.90) \\ \hline Government welfare & 416 (53.10) & 248 (54.70) & 294 (45.80) \\ \hline Self-payment & 269 (34.30) & 159 (35.10) & 280 (43.60) \\ \hline \multicolumn{5}{\|l\|}{Chronic illness} \\ \hline yes & 259 (35.60) & 141 (33.30) & 199 (34.40) & 0.68 \\ \hline no & 469 (64.40) & 286 (66.70) & 379 (65.60) \\ \hline \multicolumn{5}{\|l\|}{Accommodation} \\ \hline Owner & 566 (72.80) & 322 (72.20) & 436 (69.40) & 0.36 \\ \hline Renting & 212 (27.20) & 124 (27.80) & 192 (30.60) \\ \hline \multicolumn{5}{\|l\|}{Occupation} \\ \hline Business owner & 51 (7.10) & 33 (7.90) & 40 (7.0) & 0.47 \\ \hline Employee & 155 (21.70) & 98 (23.30) & 154 (27.00) \\ \hline Government worker & 121 (16.90) & 81 (19.30) & 95 (16.60) \\ \hline Student & 39 (5.50) & 20 (4.80) & 33 (5.80) \\ \hline Housewife & 234 (32.80) & 134 (31.90) & 167 (29.20) \\ \hline Unemployed & 5 (0.70) & 1 (0.20) & 7 (1.20) \\ \hline Disabled & 14 (2.00) & 10 (2.40) & 15 (2.60) \\ \hline Retired & 95 (13.30) & 43 (10.20) & 60 (10.50) \\ \hline \multicolumn{5}{\|l\|}{Income (Baht/month)} \\ \hline $<$ 5,000 & 50 (14.20) & 68 (21.20) & 33 (15.20) & 0.13 \\ \hline 5,001–10,000 & 113 (32.10) & 106 (33.00) & 66 (30.40) \\ \hline 10,001–30,000 & 160 (45.50) & 131 (40.80) & 108 (49.80) \\ \hline 30,001–50,000 & 21 (6.00) & 11 (3.40) & 6 (2.80) \\ \hline $>$50,000 & 8 (2.30) & 5 (1.60) & 4 (1.80) \\ \hline \end{tabular}} \end{table}	PMC1852109_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Variables} & \textbf{N (\%)} & \textbf{Mean} & \textbf{Std. Deviation} & \textbf{Min} & \textbf{Max} \\ \hline Gender & 12376 & - & - & - & - \\ \hline Males & 5660 (45.3) & - & - & - & - \\ \hline Females & 6716 (54.3) & - & - & - & - \\ \hline Body Mass Index & 10961§ & 25.75 & 4.84 & 9.60 & 57.80 \\ \hline Under/Normal weight & 5449 (49.7) & - & - & - & - \\ \hline Overweight & 3710 (33.8) & - & - & - & - \\ \hline Obese & 1802 (16.4) & - & - & - & - \\ \hline Depression (\# years with MDE-lifetime) & 12282§ & 0.41 & 8.20 & 0 & 67.00 \\ \hline No depression (0 years) & 10826 (88.1) & - & - & - & - \\ \hline Yes depression & 1456 (11.9) & - & - & - & - \\ \hline Physical Activity & 12375§ & 2.27 & 2.34 & 0 & 28.70 \\ \hline Stress Management & 12352§ & 2.31 & 0.93 & 1 & 5 \\ \hline Eating Habits & 1812§ & 10.63 & 8.85 & 0 & 62 \\ \hline Relatives with Depression & 1512§ & 1.76 & 3.02 & 0 & 55 \\ \hline \end{tabular}} \end{table}	PMC1868752_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Ages (years)} & \textbf{\% Seronegative} & \textbf{Risk among pregnancies* women/100 seronegative} & \textbf{Risk for pregnancies all women/100} & \textbf{pregnancies No. live-birth (100's)†} & \textbf{primary live-birth No. women infection pregnancies with during} \\ \hline \multicolumn{6}{\|l\|}{Non-Hispanic White} \\ \hline 12–19 & 61.0 & 0.15 & 0.09 & 2320 & 209 \\ \hline 20–29 & 56.7 & 1.38 & 0.78 & 12140 & 9469 \\ \hline 30–39 & 49.4 & 1.38 & 0.68 & 9120 & 6201 \\ \hline 40–49 & 38.9 & 1.38 & 0.54 & 510 & 275 \\ \hline Subtotal & & & & 24090 & 16154 \\ \hline \multicolumn{6}{\|l\|}{Non-Hispanic Black} \\ \hline 12–19 & 42.6 & 7.33 & 3.12 & 1330 & 4150 \\ \hline 20–29 & 17.8 & 3.40 & 0.61 & 3060 & 1867 \\ \hline 30–39 & 13.4 & 3.40 & 0.46 & 1350 & 621 \\ \hline 40–49 & 5.3 & 3.40 & 0.18 & 80 & 14 \\ \hline Subtotal & & & & 5820 & 6652 \\ \hline \multicolumn{6}{\|l\|}{Mexican American} \\ \hline 12–19 & 30.1 & 2.21 & 0.67 & 1220 & 817 \\ \hline 20–29 & 17.5 & 3.85 & 0.67 & 3990 & 2673 \\ \hline 30–39 & 10.5 & 3.85 & 0.40 & 1700 & 680 \\ \hline 40–49 & 6.8 & 3.85 & 0.26 & 100 & 26 \\ \hline Subtotal & & & & 7010 & 4196 \\ \hline Total & & & & 36940 & 27002 \\ \hline \end{tabular}} \end{table}	PMC1925089_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Drug usea} & \multicolumn{2}{\|l\|}{\textbf{Invasion}} & \multicolumn{2}{\|l\|}{\textbf{Noninvasive}} & \multicolumn{2}{\|l\|}{\textbf{TP53 IHC Intensity}} \\ \hline & \textbf{Noninvasive OR (95\%CI)b} & \textbf{Invasive OR (95\%CI)b} & \textbf{Low OR (95\%CI)b grade} & \textbf{High OR (95\%CI)b grade} & \textbf{$<$3 OR (95\%CI)b} & \textbf{3+ OR (95\%CI)b} \\ \hline \\ \hline Phenacetin & 2.4 (1.3–4.5) & 2.2 (0.9–5.1) & 2.2 (1.1–4.2) & 4.3 (1.0–17.9) & 2.0 (1.1–3.8) & 2.7 (1.2–6.5) \\ \hline Paracetamol & 0.6 (0.3–1.1) & 1.1 (0.5–2.2) & 0.5 (0.2–0.9) & 2.0 (0.6–6.4) & 0.4 (0.2–0.8) & 1.7 (0.8–3.5) \\ \hline All NSAIDs & 0.7 (0.4–1.0) & 0.5 (0.3–1.0) & 0.7 (0.5–1.1) & 0.4 (0.1–1.4) & 0.8 (0.5–1.2) & 0.5 (0.3–0.9) \\ \hline Aspirin & 0.6 (0.3–1.0) & 0.4 (0.2–0.9) & 0.6 (0.4–1.0) & 0.5 (0.1–1.8) & 0.7 (0.4–1.1) & 0.4 (0.2–0.9) \\ \hline Ibuprofen & 0.7 (0.4–1.3) & 0.7 (0.3–1.6) & 0.8 (0.4–1.4) & 0.3 (0.0–2.3) & 0.9 (0.5–1.6) & 0.6 (0.2–1.4) \\ \hline \end{tabular}} \end{table}	PMC2018698_table_3
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{. . . . Diseases} & \textbf{Age} & \multicolumn{2}{\|l\|}{\textbf{a}} & \multicolumn{2}{\|l\|}{\textbf{b}} & \multicolumn{2}{\|l\|}{\textbf{c}} & \multicolumn{4}{\|l\|}{\textbf{MAPE (\%)}} \\ \hline \textbf{. . . .} & & & & & & & & \multicolumn{2}{\|l\|}{\textbf{h = 2}} & \multicolumn{2}{\|l\|}{\textbf{h = 3}} \\ \hline \textbf{. . . .} & & & & & & & & \textbf{MHW} & \textbf{SA3} & \textbf{MHW} & \textbf{SA3} \\ \hline . . . . Diarrhea & 0–11 mo. & 0.01 & (0.03) & ,0.01 & (0.16) & 0.35 & (0.14) & 26.6 & 30.3 & 25.3 & 30.1 \\ \hline . . . . & 1–4 yr. & 0.01 & (0.02) & ,0.01 & (0.04) & 0.32 & (0.16) & 23.2 & 30.3 & 22.8 & 30.2 \\ \hline . . . . & 5–15 yr. & ,0.01 & (0.02) & 0.02 & (0.21) & 0.32 & (0.17) & 42.4 & 43.3 & 43.5 & 44.1 \\ \hline . . . & .15 yr. & 0.11 & (0.19) & 0.03 & (0.15) & 0.23 & (0.17) & 26.2 & 32.9 & 27.0 & 33.8 \\ \hline . . . . ARI & 0–11 mo. & 0.21 & (0.32) & ,0.01 & (,0.01) & 0.24 & (0.21) & 25.2 & 25.7 & 25.0 & 26.8 \\ \hline . . . . & 1–4 yr. & 0.03 & (0.07) & ,0.01 & (0.02) & 0.31 & (0.19) & 22.5 & 28.2 & 22.9 & 30.0 \\ \hline . . . . & 5–15 yr. & 0.07 & (0.09) & ,0.01 & (,0.01) & 0.30 & (0.15) & 25.9 & 25.3 & 26.3 & 26.7 \\ \hline . . . & .15 yr. & 0.23 & (0.30) & ,0.01 & (,0.01) & 0.30 & (0.20) & 24.1 & 27.1 & 25.0 & 30.0 \\ \hline . . . . Malaria & 0–11 mo. & 0.08 & (0.09) & ,0.01 & (,0.01) & 0.27 & (0.14) & 22.9 & 23.2 & 22.4 & 25.9 \\ \hline . . . . & 1–4 yr. & 0.18 & (0.22) & ,0.01 & (0.22) & 0.24 & (0.13) & 23.1 & 28.4 & 22.9 & 30.5 \\ \hline . . . & 5–15 yr. & 0.09 & (0.09) & ,0.01 & (0.06) & 0.30 & (0.16) & 22.7 & 20.9 & 22.4 & 23.2 \\ \hline . . . & .15 yr. & 0.13 & (0.08) & 0.01 & (0.12) & 0.26 & (0.12) & 17.8 & 17.5 & 18.1 & 18.1 \\ \hline \end{tabular}} \end{table}	PMC2077810_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline \textbf{Sample size} & \multicolumn{3}{\|l\|}{\textbf{Power}} & \textbf{Type I error} \\ \hline & \textbf{$\beta$3 = -0.65} & \textbf{$\beta$3 = -0.95} & \textbf{$\beta$3 = -1.20} & \textbf{$\beta$3 = 0} \\ \hline 150 & 0.348 & 0.642 & 0.780 & 0.052 \\ \hline 200 & 0.540 & 0.668 & 0.894 & 0.048 \\ \hline 250 & 0.604 & 0.852 & 0.898 & 0.054 \\ \hline 300 & 0.664 & 0.884 & 0.960 & 0.046 \\ \hline 400 & 0.760 & 0.948 & 1.000 & 0.050 \\ \hline 600 & 0.876 & 1.000 & 1.000 & 0.052 \\ \hline \end{tabular}} \end{table}	PMC2099440_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline \textbf{. . . . VACCINE DOSE 1} & \multicolumn{2}{\|l\|}{\textbf{Group 1, n = 12}} & \multicolumn{2}{\|l\|}{\textbf{Group 2, n = 13}} \\ \hline \textbf{. . . .} & \textbf{n} & \textbf{\%} & \textbf{n} & \textbf{\%} \\ \hline . . . . Documented Fever .37.5 & 1 & 8 & 0 & - \\ \hline . . . . Symptoms of feverish & 2 & 17 & 4 & 31 \\ \hline . . . . Malaise & 0 & - & 4 & 31 \\ \hline . . . Arthralgia & 2 & 17 & 2 & 15 \\ \hline . . . . Headache & 0 & - & 4 & 31 \\ \hline . . . . Myalgia & 5 & 83 & 5 & 38 \\ \hline . . . Nausea/vomiting & 0 & - & 0 & - \\ \hline . . . . VACCINE DOSE 2 & \multicolumn{2}{\|l\|}{Group 1, n = 12} & \multicolumn{2}{\|l\|}{Group 2, n = 12} \\ \hline . . . . & n & \% & n & \% \\ \hline . . . Document. Fever .37.5 & 0 & - & 0 & - \\ \hline . . . . Symptoms of feverish & 1 & 8 & 4 & 33 \\ \hline . . . . Malaise & 1 & 8 & 5 & 42 \\ \hline . . . Arthralgia & 1 & 8 & 1 & 8 \\ \hline . . . . Headache & 0 & - & 3 & 25 \\ \hline . . . . Myalgia & 3 & 25 & 6 & 50 \\ \hline . . . . Nausea/vomiting & 0 & - & 1 & 8 \\ \hline . . . VACCINE DOSE 3 & \multicolumn{2}{\|l\|}{Group 1, n = 12} & \multicolumn{2}{\|l\|}{Group 2, n = 12} \\ \hline . . . . & n & \% & n & \% \\ \hline . . . . Documented Fever .37.5 & 1 & 8 & 1 & 8 \\ \hline . . . Symptoms of feverish & 1 & 8 & 4 & 33 \\ \hline . . . . Malaise & 1 & 8 & 5 & 42 \\ \hline . . . . Arthralgia & 1 & 8 & 3 & 25 \\ \hline . . . . Headache & 0 & - & 3 & 25 \\ \hline . . . Myalgia & 2 & 17 & 5 & 42 \\ \hline . . . Nausea/vomiting & 0 & - & 1 & 8 \\ \hline \end{tabular}} \end{table}	PMC2204057_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline \textbf{Class} & \textbf{Subclass} & \textbf{Number gene families of} & \textbf{Number of genes} & \textbf{Number pseudogenes of} \\ \hline ANTP & HOXL & 14 & 52 & 0 \\ \hline & NKL & 23 & 48 & 19b \\ \hline PRD & PAX & 3 & 7a & 0 \\ \hline & PAXL & 28 & 43 & 24c, d \\ \hline LIM & & 6 & 12 & 0 \\ \hline POU & & 7 & 16 & 8e \\ \hline HNF & & 2 & 3 & 0 \\ \hline SINE & & 3 & 6 & 0 \\ \hline TALE & & 6 & 20 & 10f \\ \hline CUT & & 3 & 7 & 3g \\ \hline PROS & & 1 & 2 & 0 \\ \hline ZF & & 5 & 14 & 1h \\ \hline CERS & & 1 & 5i & 0 \\ \hline Totals & & 102 & 235a & 65b-h \\ \hline \end{tabular}} \end{table}	PMC2211742_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Group} & \multicolumn{4}{\|l\|}{\textbf{\% Concentration of parasitaemia1 of IgG (mg/ml)2}} & \multicolumn{4}{\|l\|}{\textbf{\% Concentration of invasion inhibition4 of IgG (mg/ml)}} \\ \hline \\ \hline & \textbf{0.5} & \textbf{0.25} & \textbf{0.125} & \textbf{0.0625} & \textbf{0.5} & \textbf{0.25} & \textbf{0.125} & \textbf{0.0625} \\ \hline Adjuvant control & 5.66 (60.12)3 & 5.76 (61.25) & 6.13 (60.32) & 5.34 (60.58) & - & - & - \\ \hline PfAARP immune & 1.73 (60.31) & 2.63 (60.58) & 3 (60.7) & 3.24 (6013) & 69.41 & 54.34 & 51.10 & 39.4 \\ \hline MSP-142 immune & 2.07 (60.12) & 1.93 (60.12) & 2.86 (60.31) & 3.4 (60.01) & 63.50 & 66.50 & 53.30 & 36.3 \\ \hline \end{tabular}} \end{table}	PMC2253826_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline & \textbf{Tilburg} & \textbf{Groningen} \\ \hline Number of contacts between 00.00 and 08.00 h & 787 & 483 \\ \hline Number of contacts between 08.00 and 24.00 h & 3466 & 2028 \\ \hline \end{tabular}} \end{table}	PMC2265289_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline \textbf{Estimators} & \multicolumn{2}{\|l\|}{\textbf{Lung cancer}} & \multicolumn{2}{\|l\|}{\textbf{Cervix cancer}} \\ \hline & \textbf{Dispersion variance} & \textbf{Prediction variance} & \textbf{Dispersion variance} & \textbf{Prediction variance} \\ \hline True risk values & 9.817 & - & 1.153 & - \\ \hline Global Empirical Bayes & 6.059 & - & 0.537 & - \\ \hline Local Empirical Bayes & 7.905 & - & 1.063 & - \\ \hline BYM model & 7.034 & 2.791 & 0.757 & 0.347 \\ \hline Point Poisson kriging (adjacent counties) & 7.835 & 2.542 & 1.006 & 0.338 \\ \hline ATA Poisson kriging (adjacent counties) & 7.563 & 2.363 & 0.977 & 0.287 \\ \hline ATA Poisson kriging (32 neighbors) & 7.400 & 2.297 & 0.830 & 0.237 \\ \hline \end{tabular}} \end{table}	PMC2276482_table_3
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline \textbf{Variable} & \multicolumn{2}{\|l\|}{\textbf{Significance}} \\ \hline \textbf{Muscle Total CoQ10 (mcg/mg) T2 pre ¥} & \textbf{r value} & \textbf{0.423} \\ \hline & p value & 0.007 \\ \hline Muscle Total CoQ10 (mcg/mg) T2 post & r value & 0.189 \\ \hline & p value & 0.250 \\ \hline Muscle Total CoQ10 (mcg/mg) T3 pre & r value & 0.247 \\ \hline & p value & 0.125 \\ \hline Muscle Total CoQ10 (mcg/mg) T3 post & r value & 0.244 \\ \hline & p value & 0.134 \\ \hline Oxygen Consumption (mL·kg-1·min-1) T1 ¥ & r value & 0.389 \\ \hline & p value & 0.013 \\ \hline Oxygen Consumption (mL·kg-1·min-1) T2 ¥ & r value & 0.381 \\ \hline & p value & 0.017 \\ \hline Oxygen Consumption (mL·kg-1·min-1) T3 ¥ & r value & 0.429 \\ \hline & p value & 0.006 \\ \hline Time to exhaustion (Min) T1 ¥ & r value & 0.419 \\ \hline & p value & 0.007 \\ \hline Time to exhaustion (Min) T2 ¥ & r value & 0.454 \\ \hline & p value & 0.004 \\ \hline Time to exhaustion (Min) T3 ¥ & r value & 0.485 \\ \hline & p value & 0.001 \\ \hline \end{tabular}} \end{table}	PMC2315638_table_7
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline \textbf{Coding regions} & \textbf{Number of genotypes} & \textbf{Minimum intragenotype similarity} & \textbf{Maximum intergenotype similarity} \\ \hline N & 8* & 83,3 & 80,3 \\ \hline & 7 & 80,3 & 79,8 \\ \hline N,P,M,G,L & 8* & 81,6 & 76,4 \\ \hline & 7 & 76,3 & 76,4 \\ \hline \end{tabular}} \end{table}	PMC2327259_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|} \hline & & \textbf{N} & \textbf{Ne} & \textbf{H} & \textbf{He} \\ \hline MCL1 & real time RT-PCR & 1 & 2.97 & 5.53 & 8.24 \\ \hline & DNA microarray & 1 & 3.44 & 3.92 & 5.27 \\ \hline BAK 1 & real time RT-PCR & 1 & 3.37 & 0.96 & 2.92 \\ \hline & DNA microarray & 1 & 3.42 & 0.75 & 2.13 \\ \hline GPX1 & real time RT-PCR & 1 & 4.04 & 0.94 & 2.21 \\ \hline & DNA microarray & 1 & 2.88 & 0.69 & 1.43 \\ \hline CDKN1A & real time RT-PCR & 1 & 3.65 & 0.72 & 2.44 \\ \hline & DNA microarray & 1 & 3.02 & 0.52 & 1.64 \\ \hline JUN & real time RT-PCR & 1 & 1.45 & 5.54 & 4.36 \\ \hline & DNA microarray & 1 & 1.66 & 2.33 & 3.28 \\ \hline \end{tabular}} \end{table}	PMC2330149_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Step} & \textbf{No. SNPs} & \textbf{0} & \textbf{1} & \textbf{2} & \textbf{3} & \textbf{4} & \textbf{5} & \textbf{6} & \textbf{7} & \textbf{8} & \textbf{9} & \textbf{$\geq$10} \\ \hline 1 & Availablea & 1286 & 413 & 310 & 614 & 417 & 148 & 169 & 59 & 16 & 16 & 14 \\ \hline & AICb & 1286 & 1697 & 350 & 107 & 17 & 3 & 1 & 1 & 0 & 0 & 0 \\ \hline & p $\leq$ 0.01c & & 245 & 43 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ \hline & p $\leq$ 0.001c & & 88 & 5 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ \hline 3 & Linkagesd & 294 & 81 & 76 & 118 & 141 & 102 & 101 & 102 & 110 & 91 & 2264 \\ \hline & AIC & 294 & 664 & 362 & 295 & 270 & 236 & 187 & 147 & 127 & 101 & 645 \\ \hline & p $\leq$ 0.01c & & 930 & 433 & 188 & 101 & 58 & 38 & 21 & 11 & 11 & 32 \\ \hline & p $\leq$ 0.001c & & 572 & 151 & 60 & 25 & 12 & 10 & 3 & 6 & 2 & 2 \\ \hline \end{tabular}} \end{table}	PMC2367558_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Genotypes} & \multicolumn{2}{\|l\|}{\textbf{Controls}} & \multicolumn{2}{\|l\|}{\textbf{All Patients}} & & & \multicolumn{4}{\|l\|}{\textbf{Premenopausal Patients}} & \multicolumn{4}{\|l\|}{\textbf{Postmenopausal Patients}} \\ \hline & \textbf{n} & \textbf{f} & \textbf{n} & \textbf{f} & \textbf{P} & \textbf{OR (95\%CI)} & \textbf{n} & \textbf{f} & \textbf{p} & \textbf{OR (95\%CI)} & \textbf{n} & \textbf{f} & \textbf{p} & \textbf{OR (95\%CI)} \\ \hline CYP2E1 (C-1091T) & 244 & & 304 & & & & 192 & & & & 111 \\ \hline CYP2E1 (C/C) & 232 & 0.95 & 296 & 0.97 & N.S & 1.91(0.72–5.22) & 186 & 0.97 & N.S & 1.6(0.55–4.89) & 109 & 0.98 & N.S & 2.82 (0.58–18.57) \\ \hline CYP2E1 (C/T) & 12 & 0.05 & 08 & 0.03 & N.S & 0.52(0.19–1.4) & 06 & 0.03 & N.S & 0.62(0.2–1.83) & 02 & 0.02 & N.S & 0.35 (0.05–1.71) \\ \hline CYP2E1 (T/T) & 00 & 0.00 & 00 & 0.00 & N.S & - & 00 & 0.00 & N.S & - & 00 & 0.00 & N.S & - \\ \hline CYP2C19 (exon5 G-A) & 240 & & 304 & & & & 193 & & & & 109 \\ \hline CYP2C19 (G/G) & 197 & 0.822 & 239 & 0.787 & N.S & 0.8(0.51–1.26) & 155 & 0.804 & N.S & 0.89(0.53–1.49) & 83 & 0.762 & N.S & 0.7 (0.39–1.25) \\ \hline CYP2C19 (A/G) & 41 & 0.170 & 61 & 0.200 & N.S & 1.22(0.77–1.93) & 37 & 0.191 & N.S & 1.15(0.68–1.94) & 23 & 0.211 & N.S & 1.30 (0.71–2.38) \\ \hline CYP2C19 (A/A) & 02 & 0.008 & 04 & 0.013 & N.S & 1.59(0.25–12.56) & 01 & 0.005 & N.S & 0.62(0.02–8.76) & 03 & 0.027 & N.S & 3.37 (0.45–29.24) \\ \hline CYP2D6 (G1934A) & 230 & & 300 & & & & 189 & & & & 109 \\ \hline CYP2D6 (G/G) & 167 & 0.726 & 235 & 0.783 & N.S & 1.36(0.9–2.07) & 145 & 0.767 & N.S & 1.24(0.78–1.99) & 90 & 0.827 & 0.04 & 1.79 (0.97–3.31) \\ \hline CYP2D6 (G/A) & 56 & 0.243 & 58 & 0.193 & N.S & 0.74(0.48–1.15) & 41 & 0.217 & N.S & 0.86(0.53–1.42) & 15 & 0.137 & 0.02 & 0.5 (0.25–0.96) \\ \hline CYP2D6 (A/A) & 07 & 0.031 & 07 & 0.023 & N.S & 0.76(0.24–2.48) & 03 & 0.016 & N.S & 0.51(0.1–2.24) & 04 & 0.036 & N.S & 1.21 (0.29–4.74) \\ \hline mEH (T348C) & 244 & & 306 & & & & 194 & & & & 110 \\ \hline mEH1 (Tyr/Tyr) & 113 & 0.463 & 149 & 0.486 & N.S & 1.1(0.77–1.56) & 97 & 0.500 & N.S & 1.16(0.78–1.72) & 52 & 0.472 & N.S & 1.04 (0.65–1.67) \\ \hline mEH2 (Tyr/His) & 115 & 0.471 & 119 & 0.388 & N.S & 0.71(0.5–1.02) & 70 & 0.360 & 0.02 & 0.63(0.42–0.95) & 47 & 0.427 & N.S & 0.84 (0.52–1.35) \\ \hline mEH3 (His/His) & 16 & 0.065 & 38 & 0.124 & 0.02 & 2.02(1.06–3.89) & 27 & 0.139 & 0.01 & 2.3(1.15–4.64) & 11 & 0.1 & N.S & 1.58 (0.66–3.77) \\ \hline NAT2 & 237 & & 290 & & & & 184 & & & & 105 \\ \hline Rapid Acetylators & 14 & 0.059 & 24 & 0.082 & N.S & 1.44(0.69–3) & 18 & 0.097 & N.S & 1.73(0.79–3.79) & 06 & 0.057 & N.S & 0.97 (0.32–2.79) \\ \hline Intermediate Acetylators & 105 & 0.443 & 92 & 0.317 & N.S & 0.58(0.4–0.85) & 61 & 0.331 & N.S & 0.62(0.41–0.95) & 30 & 0.285 & 0.006 & 0.52 (0.3–0.85) \\ \hline Slow Acetylators & 118 & 0.497 & 174 & 0.600 & 0.01 & 1.51(1.05–2.17) & 105 & 0.570 & N.S & 1.34(0.89–2.01) & 69 & 0.657 & 0.006 & 1.93 (1.17–3.2) \\ \hline \end{tabular}} \end{table}	PMC2377277_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline \textbf{Study} & \textbf{Outcome} & \textbf{Relative Risk/Incident Density Ratio (95\% CI)} \\ \hline Luby, Agboatwalla et al 2004 [50] & Diarrhoea \\ \hline RCT & Mean Incidence \\ \hline Quality Score 6a & Antibiotic Soap & 0.50 (0.36, 0.63) \\ \hline & Plain Soap & 0.47 (0.35, 0.59) \\ \hline Shahid, Greenough et al 1996 [43] & Diarrhoea \\ \hline CBA & Age groups \\ \hline Quality Score 1b & 0 – 11 mths & 0.39 (0.29, 0.54) \\ \hline & 12–23 mths & 0.53 (0.37, 0.77) \\ \hline & 24–59 mths & 0.44 (0.34, 0.59) \\ \hline & 6 – 9 yrs & 0.27 (0.19, 0.37) \\ \hline & 10 – 14 yrs & 0.28 (0.16, 0.49) \\ \hline & Over 15 yrs & 0.38 (0.30, 0.49) \\ \hline & All & 0.38 (0.33, 0.43) \\ \hline Wilson, Chandler et al 1991 [51] & Diarrhoea \\ \hline CBA & Children $<$11yrs & 0.21 (0.08, 0.53)c \\ \hline Quality Score 3b & Skin/Eye Disease \\ \hline & Children $<$11yrs & 2.54d \\ \hline Han, Hlaing et al 1988, 1989 [36] & Ascaris \\ \hline RCT & Children 36–59mths & 1.0d \\ \hline Quality Score 4a & Diarrhoea \\ \hline & $<$2yrs & 0.69 (0.48, 1.01)e \\ \hline & $\geq$ 2yrs & 0.67 (0.45, 0.98)e \\ \hline & All children $<$5yrs & 0.70 (0.54, 0.92)f \\ \hline & Dysentery \\ \hline & $<$2yrs & 0.59 (0.22, 1.55) \\ \hline & $\geq$ 2yrs & 1.21 (0.52, 2.80) \\ \hline & All children $<$5yrs & 0.93 (0.39, 2.23) \\ \hline \end{tabular}} \end{table}	PMC2397399_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline \textbf{Strain (a)} & \textbf{Mic-PCC7806} & \textbf{Mic-NIES843} \\ \hline Genome length & 5.17 Mb (116 Contigs) & 5.84 Mb \\ \hline rRNA loci & 2 & 2 \\ \hline tRNA loci & 41 & 42 \\ \hline Number of CDSs & 5292 & 6312 \\ \hline Putative transposases (COG similarity) & 362 (6.8\%) & 469 (7.4\%) \\ \hline Proteins linked by BDBH & 3322 (63\%) & 3322 (53\%) \\ \hline Proteins absent in the other Microcystis genome (b) & 838 (16\%) & 1760 (28\%) \\ \hline Strain-specific proteins (c) & 644/838 (76\%) & 1484/1760 (84\%) \\ \hline Large repeats (d) & 11.7\% & 11.7\% \\ \hline \end{tabular}} \end{table}	PMC2442094_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|} \hline & \textbf{Lbx1/Tlx1 locus} & \textbf{Former Lbx4/Tlx4 locus} & \textbf{(Former locus Lbx3)/Tlx3} & \textbf{Lbx2/Tlx2 locus} & \textbf{Lbx-less Nkx3.2 locus} & \textbf{Lbx2/Tlx2 loci} \\ \hline & & & & amniotes & tetrapods & teleosts \\ \hline Msx & & & Msx2 \\ \hline Nkx2/tin & Nkx2.3 & Nkx2.6 & Nkx2.5 \\ \hline Nkx3/bap & & Nkx3.1 & & & Nkx3.2 & Nkx3.2 \\ \hline & & (chicken: Nkx2.8 only) \\ \hline Nkx6 & & Nkx6.3 \\ \hline Lbx & Lbx1 & & & Lbx2 & & Lbx2 \\ \hline Tlx & Tlx1 & & Tlx3 & Tlx2 & & Tlx2 \\ \hline Pol & Poll & Polb \\ \hline Dpcd & Dpcd \\ \hline Fbxw4 & Fbxw4 \\ \hline Fbxw7 & & & & & Fbxw7 & Fbxw7 \\ \hline Slc2a15 & Slc2a15 & & & & Slc2a9 (tetrapods) \\ \hline Aup & & & & Aup1 & & Aup1 \\ \hline Pcgf1 & & & & Pcgf1 & & Pcgf1 \\ \hline Fbxw11/Btrc & Btrc & & Fbxw11/Btrc2 \\ \hline Mgea & Mgea5 & & & Mgea2 (chicken) & & Mgea2 \\ \hline Kazald & Kazald1 (tetrapods) & Kazald3 (fish) & & Kazald2 (zebrafish) \\ \hline Ldb & Ldb1 & & & & Ldb2 & Ldb2 \\ \hline Prom & Prom3 (fish) & Prom2 (tetrapods)* & & & Prom1 & Prom1 \\ \hline Loxl & Loxl4 & Loxl2 & & Loxl3 & & Loxl3 \\ \hline Slit & Slit1 & & Slit3 & & Slit2 & Slit2 \\ \hline Dok & & Dok2 & Dok3 & Dok1 & & Dok1 \\ \hline Fgf & Fgf8 & Fgf17 & Fgf18 & & & Fgf24 \\ \hline Npm & Npm3 & Npm2 & Npm1 & & & Npm4 \\ \hline Kcnip & Kcnip2 & Kcnip3* & Kcnip1 & & Kcnip4 & Kcnip4 \\ \hline \end{tabular}} \end{table}	PMC2446394_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|} \hline \textbf{Characteristic} & \textbf{n (\%)a} \\ \hline \multicolumn{2}{\|l\|}{Sex} \\ \hline Male & 234 (55.7) \\ \hline Female & 186 (44.3) \\ \hline Age (years) & 68.2 $\pm$ 13.8 \\ \hline $<$ 65 & 138 (32.9) \\ \hline 65–79 & 198 (47.1) \\ \hline $\geq$ 80 & 84 (20.0) \\ \hline History of previous stroke (n = 418) & 109 (26.1) \\ \hline Length of hospital stay (days) & 16.2 $\pm$ 21.1 \\ \hline \multicolumn{2}{\|l\|}{Stroke subtype} \\ \hline Partial anterior circulation & 132 (31.4) \\ \hline Lacunar & 106 (25.2) \\ \hline Posterior circulation & 79 (18.8) \\ \hline Total anterior circulation & 30 (7.1) \\ \hline Transient ischemic attack & 59 (14.0) \\ \hline Uncertain & 14 (3.3) \\ \hline \multicolumn{2}{\|l\|}{Stroke severity} \\ \hline Transient ischemic attack & 35 (8.4) \\ \hline Mild & 90 (21.5) \\ \hline Moderate & 226 (53.9) \\ \hline Severe & 68 (16.2) \\ \hline Unknown & 1 (0.002) \\ \hline \multicolumn{2}{\|l\|}{Disability at discharge} \\ \hline Independent & 333 (79.3) \\ \hline Dependent & 87 (20.7) \\ \hline \multicolumn{2}{\|l\|}{Cognitive impairment at discharge} \\ \hline Not impaired & 111 (26.4) \\ \hline Impaired & 84 (20.0) \\ \hline Missing & 225 (53.6) \\ \hline Atrial fibrillation (n = 418) & 60 (14.4) \\ \hline Average household income (n = 386) & \$55,472 $\pm$ 19,370 \\ \hline Total medications prescribedb & 6.4 $\pm$ 2.6 \\ \hline Total doses taken per dayb & 8.6 $\pm$ 4.5 \\ \hline Monthly cost of prescription drugsc & \$167.10 $\pm$ 99.47 \\ \hline \end{tabular}} \end{table}	PMC2474854_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Parameter [statistic]} & \textbf{patients All} & \multicolumn{3}{\|l\|}{\textbf{Olanzapine vs. non-olanzapine}} & \multicolumn{3}{\|l\|}{\textbf{Risperidone vs. non-risperidone}} & \multicolumn{3}{\|l\|}{\textbf{Haloperidol vs. non-haloperidol}} \\ \hline & & \textbf{(N OLZ = 390)} & \textbf{Non-OLZ (N = 168)} & \textbf{p-value} & \textbf{(N RIS = 72)} & \textbf{(N Non-RIS = 486)} & \textbf{p-value} & \textbf{(N HAL = 132)} & \textbf{Non-HAL (N = 426)} & \textbf{p-value} \\ \hline & \textbf{(N = 558)} \\ \hline \multicolumn{11}{\|l\|}{Previous treatmenta pharmacological} \\ \hline Any n (\%) previous medication & 291 (52.2) & 191 (49.0) & 100 (59.5) & 0.022 & 45 (62.5) & 246 (50.6) & 0.060 & 64 (48.5) & 227 (53.3) & 0.335 \\ \hline Any antipsychotic n (\%) & 214 (38.4) & 130 (33.3) & 84 (50.0) & $<$ .001 & 38 (52.8) & 176 (36.2) & 0.007 & 52 (39.4) & 162 (38.0) & 0.778 \\ \hline Olanzapine, n (\%) & 52 (9.3) & 48 (12.3) & 4 (2.4) & & 5 (6.9) & 47 (9.7) & & 13 (9.8) & 39 (9.2) \\ \hline Risperidone, n (\%) & 50 (9.0) & 26 (6.7) & 24 (14.3) & & 30 (41.7) & 20 (4.1) & & 11 (8.3) & 39 (9.2) \\ \hline Haloperidol, n (\%) & 45 (8.1) & 30 (7.7) & 15 (8.9) & & 5 (6.9) & 40 (8.2) & & 25 (18.9) & 20 (4.7) \\ \hline Quetiapine, n (\%) & 19 (3.4) & 6 (1.5) & 13 (7.7) & & 0 (0.0) & 19 (3.9) & & 4 (3.0) & 15 (3.5) \\ \hline Any benzodiazepine n (\%) & 106 (19.0) & 75 (19.2) & 31 (18.5) & 0.830 & 10 (13.9) & 96 (19.8) & 0.236 & 22 (16.7) & 84 (19.7) & 0.435 \\ \hline Lorazepam, n (\%) & 51 (9.1) & 36 (9.2) & 15 (8.9) & & 6 (8.3) & 45 (9.3) & & 14 (10.6) & 37 (8.7) \\ \hline Diazepam, n (\%) & 43 (7.7) & 29 (7.4) & 14 (8.3) & & 3 (4.2) & 40 (8.2) & & 7 (5.3) & 36 (8.5) \\ \hline Mood stabilizer n (\%) & 67 (12.0) & 48 (12.3) & 19 (11.3) & 0.939 & 7 (9.7) & 60 (12.3) & 0.568 & 11 (8.3) & 56 (13.1) & 0.141 \\ \hline Antidepressants n (\%) & 64 (11.5) & 47 (12.1) & 17 (10.1) & 0.679 & 8 (11.1) & 56 (11.5) & 0.976 & 9 (6.8) & 55 (12.9) & 0.056 \\ \hline Antipsychotic monotherapy n (\%) & 227 (40.7) & 183 (46.9) & 44 (26.2) & $<$ .001 & 13 (18.1) & 214 (44.0) & $<$ .001 & 11 (8.3) & 216 (50.7) & $<$ .001 \\ \hline \multicolumn{11}{\|l\|}{Concomitant benzodiazepine use} \\ \hline Any (\%) [95\% benzodiazepine CI (\%)] use n & [65.7–73.5] 389 (69.7) & [63.9–73.3] 268 (68.7) & [64.6–78.7] 121 (72.0) & 0.436 & [60.4–82.1] 52 (72.2) & [65.0–73.4] 337 (69.3) & 0.620 & [75.9–89.3] 110 (83.3) & [60.8–70.0] 279 (65.5) & $<$ .001 \\ \hline Lorazepam, n (\%) & 248 (44.4) & 177 (45.4) & 71 (42.3) & & 35 (48.6) & 213 (43.8) & & 65 (49.2) & 183 (43.0) \\ \hline Diazepam, n (\%) & 175 (31.4) & 109 (27.9) & 66 (39.3) & & 29 (40.3) & 146 (30.0) & & 75 (56.8) & 100 (23.5) \\ \hline Other, n (\%) & 64 (11.5) & 38 (9.7) & 26 (15.5) & & 12 (16.7) & 52 (10.7) & & 12 (9.1) & 52 (12.2) \\ \hline Benzodiazepine mean (SD), mg doseb & 81.3 (58.1) & 77.9 (52.5) & 89.0 (68.5) & 0.081 & 86.4 (72.5) & 80.6 (55.6) & 0.497 & 76.4 (50.6) & 83.3 (60.8) & 0.296 \\ \hline \end{tabular}} \end{table}	PMC2507712_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline \textbf{Risk of dissatisfaction} & \textbf{Public (\%)} & \textbf{Private (\%)} & \textbf{All (\%)} \\ \hline Properly identified specimen & 3/10(30.0) & 1/4(25.0) & 4/14(28.6) \\ \hline Clear and accurate test request & 4/10 (40.0) & 2/4(50.0) & 6/14(42.9) \\ \hline Properly collected and transported specimen & 3/10(30.0) & 1/4(25.0) & 4/14(28.6) \\ \hline Availability of equipment & 4/10 (40.0) & 1/4(25.0) & 5/14(35.7) \\ \hline Communication between laboratories & 4/10 (40.0) & 2/4(50.0) & 6/14(42.9) \\ \hline Timely results feed back to the sending laboratory & 1/10(10.0) & 1/4(25.0) & 2/14(14.5) \\ \hline \end{tabular}} \end{table}	PMC2518553_table_3
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline \textbf{Gene Category} & \textbf{Genes Upregulated} & \textbf{Genes Downregulated} \\ \hline Protein Transport & 6 & 2 \\ \hline Ion Transport & 6 & 3 \\ \hline Proliferation & 2 & 2 \\ \hline Differentiation & 2 & 2 \\ \hline Anti-apoptosis/Survival & 3 & 1 \\ \hline Transcription & 10 & 4 \\ \hline Metabolism & 5 & 6 \\ \hline Structural & 5 & 4 \\ \hline Adhesion & 4 & 1 \\ \hline Protein Synthesis & 7 & 0 \\ \hline Immune Response \& Inflammation & 4 & 1 \\ \hline Signal Transduction & 5 & 3 \\ \hline Cell Cycle \& DNA repair & 5 & 2 \\ \hline Miscellaneous & 3 & 4 \\ \hline \end{tabular}} \end{table}	PMC2533024_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline \textbf{Species} & \textbf{\# genes amplified1} & \textbf{\# disrupted genes} & \textbf{\% disrupted} \\ \hline A449 & 162 & 16 & 100 \\ \hline A449 cDNA & 16 & 16 & 100 \\ \hline A. salmonicida subsp. salmonicida ATCC 33658T & 15 & 15 & 100 \\ \hline A. salmonicida subsp. salmonicida ATCC 51413 (non-pigmented) & 16 & 16 & 100 \\ \hline A. salmonicida subsp. masoucida ATCC 27013T & 13 & 3 & 23 \\ \hline A. salmonicida subsp. achromogenes ATCC 33659T & 14 & 3 & 21 \\ \hline A. salmonicida subsp. smithia ATCC 49393T & 15 & 4 & 27 \\ \hline A. bestarium ATCC 51108T & 7 & 0 & 0 \\ \hline A. veronii bv. sobria ATCC 9071 & 4 & 0 & 0 \\ \hline A. sobria ATCC 43979T & 2 & 0 & 0 \\ \hline A. caviae ATCC 15468T & 2 & 0 & 0 \\ \hline A. hydrophila ATCC 7966T & 132 & 0 & 0 \\ \hline \end{tabular}} \end{table}	PMC2556355_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline \textbf{Characteristic} & \textbf{PD (n = 57)} & \textbf{Controls (n = 51)} \\ \hline Age at study (mean6SD), years & 62.369.1 & 63.768.7 \\ \hline Age at onset (mean6SD), years & 58.269.1 & N/A \\ \hline Range of age at onset, years & 40–75 & N/A \\ \hline Onset before age 50, n (\%) & 7 (12.3) & N/A \\ \hline Asymmetry of tremors or rigidity at onset, n (\%) & 57 (100) & N/A \\ \hline Bradykinesia, n (\%) & 57 (100) & N/A \\ \hline Parkinsonian tremor, n (\%) & 57 (100) & N/A \\ \hline Rigidity, n (\%) & 57 (100) & N/A \\ \hline Postural abnormality, n (\%) & 31 (54.4) & N/A \\ \hline Gait abnormality, n (\%) & 48 (84.2) & N/A \\ \hline Levodopa responsiveness, n (\%)* & 54 (94.7) & N/A \\ \hline MMSE [mean6SD (range)] & 28.362.1 (19–30) & N/A \\ \hline Hoehn \& Yahr stage [median (range)] & 2 (1–4) & N/A \\ \hline UPDRS - motor subscale [mean6SD (range)] & 35.1612.6 (10–66) & N/A \\ \hline Family history of tremors in a first-degree relative, n (\%) & 9 (15.8) & N/A \\ \hline \end{tabular}} \end{table}	PMC2559870_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline \textbf{Stage of labour} & \textbf{Definition of stage and phase} & \textbf{Diagnostic Criteria for Dystocia} \\ \hline First stage & From cervical onset dilatation of regular to full contractions dilatation of leading cervix to \\ \hline Latent phase & Cervix 0 – 3.9 cm dilatation & The diagnosis was not to be given in this phase \\ \hline Active phase & Cervix $\geq$ 4 cm dilatation & $<$ 1/2 cm dilatation of cervix per hour, assessed over 4 hours = dystocia \\ \hline Second stage & From full dilatation of cervix to the child is born \\ \hline Descending phase & From and irresistible full dilatation urge of to cervix push to strong & $>$ If $>$ epidural 2 3 hours hours without is = administered: dystocia descent = dystocia. \\ \hline Expulsive phase & Strong major part and of irresistible the contraction pushing during the & $>$ 1 hour without progress = dystocia \\ \hline \end{tabular}} \end{table}	PMC2569907_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline \textbf{Lipid variable} & \textbf{Educational status} & \textbf{Obesity} & \textbf{Truncal obesity} \\ \hline Total Cholesterol $\geq$ 200 mg/dl & 0.450 (0.072) & 0.322 (0.120) & 0.773 (0.011) \\ \hline LDL Cholesterol $\geq$ 130 mg/dl & 0.529 (0.051) & 0.462 (0.069) & 0.737 (0.014) \\ \hline HDL Cholesterol $<$ 40 mg/dl & 0.347 (0.109) & 0.352 (0.107) & 0.477 (0.064) \\ \hline Non-HDL Cholesterol $\geq$ 160 mg/dl & 0.531 (0.050) & 0.421 (0.082) & 0.884 (0.003) \\ \hline Remnant cholesterol $\geq$ 25 mg/dl & -0.211 (0.179) & -0.257 (0.152) & -0.0711 (0.305) \\ \hline Total:HDL cholesterol ratio $\geq$ 5.0 & 0.469 (0.067) & 0.456 (0.071) & 0.593 (0.037) \\ \hline Total:HDL cholesterol ratio $\geq$ 4.0 & 0.535 (0.049) & 0.480 (0.061) & 0.768 (0.011) \\ \hline Triglycerides $\geq$ 150 mg/dl & -0.111 (0.259) & -0.196 (0.189) & 0.099 (0.272) \\ \hline \end{tabular}} \end{table}	PMC2579290_table_3
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Analyses} & \textbf{Dose Group} & \multicolumn{3}{\|l\|}{\textbf{Proportion of Responders}} & \multicolumn{2}{\|l\|}{\textbf{SBA Titers four weeks after vaccination}} \\ \hline & & \textbf{n/N} & \textbf{\%} & \textbf{95\% CI} & \textbf{GMT} & \textbf{95\% CI} \\ \hline \multicolumn{7}{\|l\|}{Serogroup A} \\ \hline MITT & Full & 249/289 & 86.2 & 82.2–90.2 & 3607.1 & 2952.8–4406.3 \\ \hline & 1/5 dose & 173/224 & 77.2 & 71.7–82.7 & 2035.4 & 1600.1–2589.0 \\ \hline & 1/10 dose & 159/230 & 69.1 & 63.2 -75.0 & 1367.6 & 1083.1–1726.8 \\ \hline PP & Full & 247/287 & 86.1 & 82.1–90.1 & 3612.6 & 2953.3–4419.1 \\ \hline & 1/5 dose & 172/222 & 77.5 & 72.0–83.0 & 2054.4 & 1612.2–2618.0 \\ \hline & 1/10 dose & 159/229 & 69.4 & 63.5–75.3 & 1369.3 & 1083.3–1730.7 \\ \hline Non immune & Full & 140/148 & 94.6 & 91.0–98.2 & 1918.0 & 1426.0–2579.8 \\ \hline & 1/5 dose & 94/102 & 92.2 & 87.0–97.4 & 852.3 & 573.2–1267.5 \\ \hline & 1/10 dose & 98/111 & 88.3 & 82.4–94.2 & 754.1 & 495.3–1148.1 \\ \hline \multicolumn{7}{\|l\|}{Serogroup W135} \\ \hline MITT & Full & 269/289 & 93.1 & 90.2–96.0 & 2190.3 & 1728.9–2774.6 \\ \hline & 1/5 dose & 212/224 & 94.6 & 91.7–97.5 & 2029.1 & 1573.7–2616.2 \\ \hline & 1/10 dose & 220/231 & 95.2 & 92.5–97.9 & 2422.7 & 1979.9–2964.6 \\ \hline PP & Full & 267/286 & 93.4 & 90.5–96.3 & 2175.9 & 1714.2–2762.0 \\ \hline & 1/5 dose & 210/222 & 94.6 & 91.6–97.6 & 2041.6 & 1582.2–2634.5 \\ \hline & 1/10 dose & 219/229 & 95.6 & 93.0–98.2 & 2426.3 & 1979.7–2973.7 \\ \hline Non immune & Full & 207/221 & 93.7 & 90.5–96.9 & 1539.5 & 1160.0–2043.2 \\ \hline & 1/5 dose & 168/178 & 94.4 & 91.0–97.8 & 1517.4 & 1129.3–2039.0 \\ \hline & 1/10 dose & 172/177 & 97.2 & 94.8–99.6 & 2008.3 & 1583.0–2547.9 \\ \hline \multicolumn{7}{\|l\|}{Serogroup C} \\ \hline MITT & Full & 259/284 & 91.2 & 87.9–94.5 & 1168.3 & 911.0–1498.2 \\ \hline & 1/5 dose & 179/222 & 80.6 & 75.4–85.8 & 472.1 & 332.3–670.6 \\ \hline & 1/10 dose & 171/223 & 76.7 & 71.2–82.2 & 399.3 & 277.1–575.4 \\ \hline PP & Full & 257/282 & 91.1 & 87.8–94.4 & 1175.1 & 914.9–1509.3 \\ \hline & 1/5 dose & 177/220 & 80.4 & 75.2–85.6 & 467.3 & 328.0–665.8 \\ \hline & 1/10 dose & 170/222 & 76.6 & 71.1–82.1 & 396.3 & 274.6–572.0 \\ \hline Non immune & Full & 252/271 & 93.0 & 90.0–96.0 & 1108.5 & 858.4–1431.5 \\ \hline & 1/5 dose & 172/211 & 81.5 & 76.3–86.7 & 412.2 & 288.2–589.6 \\ \hline & 1/10 dose & 156/202 & 77.2 & 71.4–83.0 & 315.6 & 214.8–463.8 \\ \hline \multicolumn{7}{\|l\|}{Serogroup Y} \\ \hline MITT & Full & 242/286 & 84.6 & 80.4–88.8 & 936.2 & 673.7–1301.0 \\ \hline & 1/5 dose & 185/224 & 82.6 & 77.7–87.5 & 772.7 & 529.2–1128.2 \\ \hline & 1/10 dose & 194/231 & 84.0 & 79.3–88.7 & 822.6 & 569.8–1187.5 \\ \hline PP & Full & 240/284 & 84.5 & 80.3–88.7 & 924.2 & 663.8–1286.7 \\ \hline & 1/5 dose & 183/222 & 82.4 & 77.4–87.4 & 768.3 & 524.4–1125.6 \\ \hline & 1/10 dose & 193/230 & 83.9 & 79.2–88.6 & 816.8 & 565.1–1180.8 \\ \hline Non immune & Full & 238/282 & 84.4 & 80.2–88.6 & 916.8 & 657.3–1278.8 \\ \hline & 1/5 dose & 175/214 & 81.8 & 76.7–86.9 & 687.5 & 466.1–1014.1 \\ \hline & 1/10 dose & 191/228 & 83.8 & 79.0–88.6 & 798.1 & 551.1–1155.7 \\ \hline \end{tabular}} \end{table}	PMC2584372_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline \textbf{Substance} & \textbf{Sham} & \textbf{Saline} & \textbf{LPS} & \textbf{Kruskal-Wallis H(2, N = 33)} \\ \hline \multicolumn{5}{\|l\|}{Alkanes} \\ \hline Octadecane & 0,17 $\pm$ 0,11 & 0,18 $\pm$ 0,05 & 0,19 $\pm$ 0,11 & NS \\ \hline Nonadecane & 0,29 $\pm$ 0,14 & 0,35 $\pm$ 0,21 & 0,15 $\pm$ 0,04 & NS \\ \hline Eicosane & 0,09 $\pm$ 0,04 & 0,09 $\pm$ 0,03 & 0,06 $\pm$ 0,04 & NS \\ \hline Heneicosane & 1,24 $\pm$ 0,40 & 1,73 $\pm$ 0,65 & 0,84 $\pm$ 0,20 & NS \\ \hline Docosane & 0,14 $\pm$ 0,02 & 0,16 $\pm$ 0,04 & 0,11 $\pm$ 0,02 & NS \\ \hline Tricosane & 4,42 $\pm$ 0,73 & 4,70 $\pm$ 0,89 & 3,92 $\pm$ 0,39 & NS \\ \hline Tetracosane & tr & tr & tr & NS \\ \hline Pentacosane & 2,88 $\pm$ 0,66 & 2,76 $\pm$ 0,16 & 2,99 $\pm$ 0,17 & NS \\ \hline Hexacosane & 0,38 $\pm$ 0,13 & 0,38 $\pm$ 0,07 & 0,34 $\pm$ 0,04 & NS \\ \hline Heptacosane & 10,21 $\pm$ 3,91 & 9,76 $\pm$ 1,76 & 9,88 $\pm$ 1,45 & NS \\ \hline Octacosane & 0,67 $\pm$ 0,06 & 0,62 $\pm$ 0,04 & 0,59 $\pm$ 0,06 & NS \\ \hline Nonacosane & 14,15 $\pm$ 0,83 & 12,56 $\pm$ 1,52 & 12,33 $\pm$ 1,12 & NS \\ \hline Tritriacontane & 0,72 $\pm$ 0,15 & 0,76 $\pm$ 0,06 & 0,77 $\pm$ 0,06 & NS \\ \hline Hentriacontane & 17,24 $\pm$ 3,59 & 17,49 $\pm$ 1,99 & 18,70 $\pm$ 1,12 & NS \\ \hline Dotriacontane & 0,23 $\pm$ 0,06 & 0,30 $\pm$ 0,08 & 0,30 $\pm$ 0,07 & p = 0.05 \\ \hline Tritriacontane & 3,03 $\pm$ 0,93 & 4,60 $\pm$ 1,51 & 4,51 $\pm$ 1,00 & p = 0.024 \\ \hline \multicolumn{5}{\|l\|}{Alkenes} \\ \hline Nonadecene & tr & tr & tr & NS \\ \hline Tricosene & 0,30 $\pm$ 0,08 & 0,31 $\pm$ 0,06 & 0,29 $\pm$ 0,03 & NS \\ \hline Pentacosene & 0,37 $\pm$ 0,06 & 0,35 $\pm$ 0,05 & 0,32 $\pm$ 0,03 & p = 0.049 \\ \hline Heptacosene & 0,39 $\pm$ 0,11 & 0,36 $\pm$ 0,13 & 0,26 $\pm$ 0,04 & p = 0.001 \\ \hline Nonacosene & 1,17 $\pm$ 0,09 & 0,96 $\pm$ 0,10 & 0,98 $\pm$ 0,08 & p = 0.014 \\ \hline Hentriacontene Isomere1 & 4,42 $\pm$ 0,47 & 4,23 $\pm$ 0,21 & 4,37 $\pm$ 0,52 & NS \\ \hline Hentriacontene Isomere 2 & 6,17 $\pm$ 0,52 & 6,06 $\pm$ 0,24 & 6,28 $\pm$ 0,61 & NS \\ \hline Dotriacontene & 0,89 $\pm$ 0,12 & 0,98 $\pm$ 0,04 & 1,02 $\pm$ 0,08 & p = 0.026 \\ \hline Tritriacontene & 16,77 $\pm$ 3,02 & 19,24 $\pm$ 0,49 & 20,30 $\pm$ 1,71 & p = 0.01 \\ \hline \multicolumn{5}{\|l\|}{Alkynes} \\ \hline Pentacosyne & tr & tr & tr & NS \\ \hline Tritriacontyne & 2,08 $\pm$ 0,46 & 2,43 $\pm$ 0,83 & 2,44 $\pm$ 0,31 & NS \\ \hline \multicolumn{5}{\|l\|}{Methylalkanes} \\ \hline 11,13,15-Methylpentacosane & 0,30 $\pm$ 0,07 & 0,29 $\pm$ 0,07 & 0,38 $\pm$ 0,04 & NS \\ \hline 11,13-Methylheptacosane & 2,39 $\pm$ 0,31 & 2,60 $\pm$ 0,58 & 2,50 $\pm$ 0,21 & NS \\ \hline 11,13,15-Methylnonacosane & 2,15 $\pm$ 0,19 & 2,34 $\pm$ 0,56 & 2,27 $\pm$ 0,24 & NS \\ \hline 11,13,15-Methylhentriacontane & 1,31 $\pm$ 0,12 & 1,43 $\pm$ 0,35 & 1,42 $\pm$ 0,15 & NS \\ \hline 11,13,15,17-Methyltritriacontane & 0,56 $\pm$ 0,07 & 0,68 $\pm$ 0,17 & 0,69 $\pm$ 0,08 & NS \\ \hline \end{tabular}} \end{table}	PMC2596086_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline \textbf{Species} & \textbf{Mineralization of the permanent dentition at birth} & \textbf{Reference} \\ \hline \multicolumn{3}{\|l\|}{Category I. Altricial: eyes closed, naked, nidicolous or ‘nest-dwelling’} \\ \hline Gray short-tail opossum, Monodelphis domestica & None & [33] \\ \hline Brown bear, Ursus arctos & None & [22] \\ \hline Indian mongoose, Herpestes auropunctatus & None & [34] \\ \hline Ferret, Mustela putorious & None & [35] \\ \hline Domestic dog, Canis familiaris & Trace & [36] \\ \hline \multicolumn{3}{\|l\|}{Category II. Precocial: eyes open, haired, nidicolous or ‘nest-dwelling’} \\ \hline Domestic pig, Sus scrofa & None & [37] \\ \hline Miniature pig, Sus scrofa & M1 cusp tips beginning to mineralize & [38] \\ \hline Collared peccary, Tayassu tajacu & M1 cusp tips formed & [39] \\ \hline \multicolumn{3}{\|l\|}{Category III. Precocial: eyes open, haired, transported (largely primates)} \\ \hline Human, Homo sapiens & M1 cusp tips beginning to mineralize & [40] \\ \hline Great apes, Pan, Gorilla, and Pongo spp. & M1 cusp tips beginning to mineralize & [40] \\ \hline Gibbon, Hylobates sp. & M1 cusp tips beginning to mineralize & [40] \\ \hline Rhesus macaque, Macaca mulaltta & M1 cusp tips formed & [41] \\ \hline Mongoose lemur, Eulemur mongoz & M1 cusp tips formed & [42] \\ \hline Coquerel’s sifaka, Propithecus verreauxi & M1 crown almost complete, M2 near coalescence, M3 trace & [42] \\ \hline Tarsier, Tarsius bancanus & M1 ‘well differentiated’ (some deciduous teeth resorbed in utero) & [43] \\ \hline \multicolumn{3}{\|l\|}{Category IV. Precocial: eyes open, haired, nidifugous or ‘nest-fleeing’} \\ \hline American tapir, Tapirus cf. T. bairdii & M1 anterior cusps connected & [44] \\ \hline Domestic sheep, Ovis aries & M1 cusps connected; crown one-quarter formed & [45] \\ \hline Maiacetus inuus1 & M1 crown one-half formed & this study \\ \hline Fallow deer, Dama dama & M1 crown one-half formed & [46] \\ \hline Pygmy hippo, Hexaprotodon liberensis & M1? (many deciduous teeth erupted at birth; large M1 crypt) & [27] \\ \hline Giraffe, Giraffa camelopardalis & M1 crown complete (all deciduous teeth erupted at birth) & [47] \\ \hline Fur seal, Callorhinus ursinus & M1-2 crowns complete (deciduous teeth shed in utero) & [48] \\ \hline Guinea pig, Cavia porcellus & All permanent teeth erupted; roots incomplete & [23] \\ \hline \end{tabular}} \end{table}	PMC2629576_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|} \hline \textbf{Family} & \textbf{Members} \\ \hline 1 & mir-466b-1 mir-466b-2 \\ \hline 2 & mir-664-1 mir-664-2 \\ \hline \end{tabular}} \end{table}	PMC2632650_table_3
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|} \hline \textbf{Term} & \textbf{Description and synonyms} \\ \hline LRTI & Lower pneumonia. very severe respiratory pneumonia. Includes tract all infection. cases identified Used synonymously as mild, severe with or \\ \hline All-cause LRTI & Non-specific lower respiratory tract infection. \\ \hline RSV-ARI & Clinical Irrespective (i.e. symptomatic) of severity. RSV antigen positive episode. \\ \hline RSV-LRTI & RSV-associated LRTI (pneumonia) and equivalent to RSV disease. \\ \hline Disease progression & Development of LRTI from upper respiratory tract infection. \\ \hline \end{tabular}} \end{table}	PMC2635480_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline \textbf{Experiment No.} & \textbf{(Theoretical) Open Voltage-V circuit} & \textbf{Open ( Voltage-V Practical) circuit} \\ \hline EX1 & 1.198 & 0.386 \\ \hline EX2 & 0.858 & 0.332 \\ \hline EX3 & 1.219 & 0.327 \\ \hline EX4 & 1.209 & 0.234 \\ \hline EX5 & 1.188 & 0.305 \\ \hline EX6 & 0.848 & 0.209 \\ \hline \end{tabular}} \end{table}	PMC2635613_table_3
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline & \multicolumn{4}{\|l\|}{\textbf{Questionnaire return}} \\ \hline & \textbf{Incomplete months for all nine} & \textbf{Complete months for all nine} & \textbf{Incomplete 9 months for 3, 6, and} & \textbf{Complete 9 months for 3, 6, and} \\ \hline attended of Poor sessions Attendance, less (n than = 11) 50\% & 11 (35.5\%) & 0 (0\%) & 11 (47.8\%) & 0 (0\%) \\ \hline attended of Good sessions Attendance, 50\% (n or = more 13) & 9 (29.0\%) & 4 (44.4\%) & 3 (13\%) & 10 (58.8\%) \\ \hline Usual Care & 11 (35.5\%) & 5 (55.6\%) & 9 (39.1\%) & 7 (41.2\%) \\ \hline Total & 31 (100\%) & 9 (100\%) & 23 (100\%) & 17 (100\%) \\ \hline \end{tabular}} \end{table}	PMC2636800_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Protein or gene} & \textbf{Ac} & \textbf{Ad} & \textbf{Na} & \textbf{Hc} & \textbf{Ans} & \textbf{Ass} & \textbf{Tc} & \textbf{Bm} & \textbf{Di} & \textbf{Ov} \\ \hline ATP6 & 85.9 & 85.4 & 86.9 & 78.8 & 73.3 & 74.3 & 74.8 & 19.8 & 21.7 & 21.2 \\ \hline COX1 & 97.3 & 96.9 & 97.3 & 94.2 & 89.7 & 90.8 & 91.6 & 50.7 & 50.9 & 51.4 \\ \hline COX2 & 89.6 & 88.3 & 92.2 & 87.4 & 79.7 & 82.7 & 81.8 & 41.4 & 41.8 & 40.5 \\ \hline COX3 & 96.0 & 95.6 & 94.5 & 91.8 & 80.7 & 82.3 & 83.5 & 33.2 & 33.2 & 32.0 \\ \hline CYTB & 87.0 & 87.0 & 83.7 & 79.1 & 69.4 & 73.2 & 72.4 & 53.2 & 51.6 & 53.5 \\ \hline NAD1 & 84.4 & 84.4 & 84.8 & 74.4 & 69.3 & 69.6 & 69.5 & 48.4 & 52.3 & 50.1 \\ \hline NAD2 & 72.5 & 71.1 & 69.7 & 50.1 & 53.5 & 48.1 & 52.2 & 35.4 & 30.8 & 35.2 \\ \hline NAD3 & 81.9 & 81.9 & 75.6 & 67.5 & 64.8 & 67.5 & 63.9 & 38.3 & 37.5 & 39.2 \\ \hline NAD4 & 79.2 & 79.4 & 80.6 & 69.6 & 67.4 & 65.0 & 65.0 & 45.2 & 44.4 & 44.1 \\ \hline NAD4L & 93.5 & 93.5 & 92.2 & 65.8 & 71.4 & 68.8 & 64.9 & 30.3 & 37.5 & 33.7 \\ \hline NAD5 & 78.5 & 77.9 & 79.1 & 67.3 & 63.2 & 64.7 & 64.5 & 42.1 & 39.1 & 39.9 \\ \hline NAD6 & 67.3 & 70.1 & 70.8 & 48.6 & 58.3 & 57.6 & 52.7 & 27.8 & 28.4 & 29.8 \\ \hline rrnL & 83.4 & 82.6 & 80.2 & 73.9 & 69.2 & 70.1 & 67.5 & 63.9 & 62.8 & 61.6 \\ \hline rrnS & 86.8 & 85.6 & 86.0 & 75.6 & 74.5 & 71.2 & 70.6 & 61.1 & 61.3 & 60.5 \\ \hline \end{tabular}} \end{table}	PMC2656527_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline & \multicolumn{3}{\|l\|}{\textbf{Odds ratio Age (95\% at menarche, confidence years interval)a, b}} \\ \hline \\ \hline \textbf{Tumor characteristic} & \textbf{11} & \textbf{$>$ 11 and 13} & \textbf{$>$ 13 and 14} \\ \hline \multicolumn{4}{\|l\|}{Tumor size} \\ \hline \multicolumn{4}{\|l\|}{1–10 mm} \\ \hline 11–20 mm & 1.00 (0.65–1.53) & 0.96 (0.74–1.25) & 1.01 (0.76–1.33) \\ \hline 21 mm & 1.05 (0.64–1.72) & 1.43 (1.06–1.92) & 1.32 (0.96–1.81) \\ \hline \multicolumn{4}{\|l\|}{Grade} \\ \hline \multicolumn{4}{\|l\|}{Low} \\ \hline Medium & 2.05 (1.00–4.19) & 1.47 (1.00–2.15) & 1.74 (1.15–2.62) \\ \hline High & 2.04 (1.01–4.16) & 1.55 (1.06–2.26) & 1.45 (1.00–2.19) \\ \hline \multicolumn{4}{\|l\|}{ER status} \\ \hline \multicolumn{4}{\|l\|}{Positive} \\ \hline Negative & 1.33 (0.82–2.16) & 0.94 (0.68–1.29) & 1.15 (0.83–1.61) \\ \hline \multicolumn{4}{\|l\|}{PR status} \\ \hline \multicolumn{4}{\|l\|}{Positive} \\ \hline Negative & 0.86 (0.54–1.36) & 0.99 (0.75–1.30) & 1.24 (0.93–1.66) \\ \hline \multicolumn{4}{\|l\|}{Lymph node involvement} \\ \hline \multicolumn{4}{\|l\|}{Absent} \\ \hline Present & 1.49 (1.02–2.19) & 1.29 (1.02–1.65) & 1.22 (0.95–1.58) \\ \hline \multicolumn{4}{\|l\|}{Histology} \\ \hline \multicolumn{4}{\|l\|}{Ductal} \\ \hline Lobular & 1.17 (0.68–2.01) & 1.08 (0.76–1.52) & 0.99 (0.68–1.43) \\ \hline All other & 0.68 (0.39–1.18) & 1.09 (0.81–1.46) & 0.92 (0.66–1.26) \\ \hline \end{tabular}} \end{table}	PMC2656904_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline \textbf{Factor} & \textbf{R2} & \textbf{P-value} \\ \hline Fasting plasma glucose & 0.0120 & NS \\ \hline HbA1c & 0.0731 & .040 \\ \hline Systolic blood pressure & 0.0133 & NS \\ \hline Diastolic blood pressure & 0.0301 & NS \\ \hline Total cholesterol (TC) & 0.0424 & NS \\ \hline HDL-C & 0.0042 & NS \\ \hline LDL-C & 0.0258 & NS \\ \hline Triglyceride (TG) & 0.0588 & NS \\ \hline Duration of diabetes & 0.0150 & NS \\ \hline Age & 0.0367 & NS \\ \hline BMI & 0.0174 & NS \\ \hline Gender & 0.0151 & NS \\ \hline \end{tabular}} \end{table}	PMC2656910_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|} \hline \textbf{COG id} & \textbf{Description} & \multicolumn{2}{\|l\|}{\textbf{Mature}} & \multicolumn{2}{\|l\|}{\textbf{Infant}} & \textbf{Metastat value q-} \\ \hline & & \textbf{Mean abundance (\%)} & \textbf{stderr} & \textbf{Mean abundance (\%)} & \textbf{stderr} \\ \hline COG0205 & 6-phosphofructokinase & 0.0017 & 0.0001 & 0.0006 & 0.0002 & 0.0313 \\ \hline COG0358 & DNA primase (bacterial type) & 0.0024 & 0.0001 & 0.0008 & 0.0001 & 0.0072 \\ \hline COG0507 & ATP-dependent superfamily I member exoDNAse (exonuclease V), alpha subunit - helicase & 0.0016 & 0.0001 & 0.0008 & 0.0001 & 0.0349 \\ \hline COG0526 & Thiol-disulfide isomerase and thioredoxins & 0.0028 & 0.0002 & 0.0014 & 0.0002 & 0.0371 \\ \hline COG0621 & 2-methylthioadenine synthetase & 0.0017 & 0.0001 & 0.0008 & 0.0002 & 0.0450 \\ \hline COG0642 & Signal transduction histidine kinase & 0.0132 & 0.0009 & 0.0070 & 0.0004 & 0.0270 \\ \hline COG0667 & Predicted oxidoreductases (related to aryl-alcohol dehydrogenases) & 0.0012 & 0.0001 & 0.0021 & 0.0001 & 0.0282 \\ \hline COG0739 & Membrane proteins related to metalloendopeptidases & 0.0024 & 0.0001 & 0.0006 & 0.0001 & 0.0072 \\ \hline COG0745 & Response a winged-helix regulators DNA-binding consisting domain of a CheY-like receiver domain and & 0.0076 & 0.0003 & 0.0051 & 0.0004 & 0.0352 \\ \hline COG0747 & ABC-type dipeptide transport system, periplasmic component & 0.0011 & 0.0001 & 0.0027 & 0.0003 & 0.0352 \\ \hline COG1113 & Gamma-aminobutyrate permease and related permeases & 0.0002 & 0.0001 & 0.0018 & 0.0003 & 0.0349 \\ \hline COG1129 & ABC-type sugar transport system, ATPase component & 0.0013 & 0.0001 & 0.0028 & 0.0003 & 0.0492 \\ \hline COG1145 & Ferredoxin & 0.0017 & 0.0001 & 0.0005 & 0.0002 & 0.0217 \\ \hline COG1196 & Chromosome segregation ATPases & 0.0017 & 0.0001 & 0.0007 & 0.0001 & 0.0108 \\ \hline COG1249 & Pyruvate/2-oxoglutarate dehydrogenase (E3) component, dehydrogenase and related complex, enzymes dihydrolipoamide & 0.0006 & 0.0001 & 0.0011 & 0.0001 & 0.0349 \\ \hline COG1263 & Phosphotransferase acetylglucosamine-specific system IIC components, glucose/maltose/N- & 0.0012 & 0.0001 & 0.0031 & 0.0003 & 0.0313 \\ \hline COG1475 & Predicted transcriptional regulators & 0.0025 & 0.0002 & 0.0014 & 0.0002 & 0.0435 \\ \hline COG1595 & DNA-directed RNA polymerase specialized sigma subunit, sigma24 homolog & 0.0053 & 0.0004 & 0.0013 & 0.0003 & 0.0206 \\ \hline COG1609 & Transcriptional regulators & 0.0030 & 0.0002 & 0.0092 & 0.0013 & 0.0424 \\ \hline COG1629 & Outer membrane receptor proteins, mostly Fe transport & 0.0120 & 0.0016 & 0.0013 & 0.0007 & 0.0313 \\ \hline COG1762 & Phosphotransferase system mannitol/fructose-specific IIA domain (Ntr-type) & 0.0004 & 0.0001 & 0.0017 & 0.0002 & 0.0293 \\ \hline COG1961 & Site-specific recombinases, DNA invertase Pin homologs & 0.0059 & 0.0004 & 0.0018 & 0.0006 & 0.0345 \\ \hline COG2204 & Response DNA-binding regulator domains containing CheY-like receiver, AAA-type ATPase, and & 0.0019 & 0.0002 & 0.0005 & 0.0002 & 0.0421 \\ \hline COG2244 & Membrane protein involved in the export of O-antigen and teichoic acid & 0.0019 & 0.0001 & 0.0009 & 0.0001 & 0.0229 \\ \hline COG2376 & Dihydroxyacetone kinase & 0.0002 & 0 & 0.0009 & 0.0001 & 0.0278 \\ \hline COG2440 & Ferredoxin-like protein & 0 & 0 & 0.0002 & 0 & 0.0394 \\ \hline COG2893 & Phosphotransferase system, mannose/fructose-specific component IIA & 0.0003 & 0.0001 & 0.0011 & 0.0001 & 0.0352 \\ \hline COG3250 & Beta-galactosidase/beta-glucuronidase & 0.0056 & 0.0004 & 0.0023 & 0.0006 & 0.0435 \\ \hline COG3451 & Type IV secretory pathway, VirB4 components & 0.0033 & 0.0001 & 0.0009 & 0.0003 & 0.0157 \\ \hline COG3505 & Type IV secretory pathway, VirD4 components & 0.0029 & 0.0001 & 0.0010 & 0.0003 & 0.0278 \\ \hline COG3525 & N-acetyl-beta-hexosaminidase & 0.0016 & 0.0002 & 0.0004 & 0.0001 & 0.0352 \\ \hline COG3537 & Putative alpha-1,2-mannosidase & 0.0020 & 0.0003 & 0.0002 & 0.0002 & 0.0352 \\ \hline COG3711 & Transcriptional antiterminator & 0.0004 & 0.0001 & 0.0020 & 0.0003 & 0.0339 \\ \hline COG3712 & Fe2+-dicitrate sensor, membrane component & 0.0023 & 0.0003 & 0 & 0 & 0.0280 \\ \hline COG4206 & Outer membrane cobalamin receptor protein & 0.0021 & 0.0003 & 0.0003 & 0.0001 & 0.0313 \\ \hline COG4771 & Outer membrane receptor for ferrienterochelin and colicins & 0.0039 & 0.0005 & 0.0006 & 0.0003 & 0.0366 \\ \hline \end{tabular}} \end{table}	PMC2661018_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline & \textbf{Saturated fatty acids} & \textbf{Linoleic acid (omega 6)} & \textbf{Total omega 3} & \textbf{Monounsaturated fatty acids} \\ \hline Corn oila & 13 & 61 & 1 & 26 \\ \hline Canola oila & 6 & 20 & 10 & 62 \\ \hline n-3 supp.b & 9 & 6 & 63 & 21 \\ \hline \end{tabular}} \end{table}	PMC2669087_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|} \hline & \multicolumn{6}{\|l\|}{\textbf{DNA sequence identity thresholds defining a cassette-type (\%)}} \\ \hline & \textbf{99} & \textbf{97} & \textbf{95} & \textbf{90} & \textbf{80} & \textbf{70} \\ \hline Number of cassette-types & 3354 & 2980 & 2774 & 2389 & 2213 & 2202 \\ \hline Shannon-Weiner Index & 7.7 & 7.5 & 7.4 & 7.1 & 6.9 & 6.9 \\ \hline Chao-1 (Standard Estimator deviation) & (198) 8536 & 6827 (104) & (231) 6258 & 5166 (200) & (182) 4638 & (182) 4638 \\ \hline \end{tabular}} \end{table}	PMC2674596_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|} \hline Relative amount, \% & L1 & L2 & H1 & H2 & H3 \\ \hline Human & 19.0 & 37.0 & 31.0 & 11.0 & 3.0 \\ \hline Chimp & 22.6 & 36.6 & 25.4 & 13.2 & 2.1 \\ \hline Dog & 23.8 & 35.5 & 23.7 & 13.4 & 3.6 \\ \hline Overall average & 21.8 & 36.4 & 26.7 & 12.5 & 2.9 \\ \hline Standard deviation & 2.5 & 0.8 & 3.8 & 1.3 & 0.8 \\ \hline Chicken & 17.4 & 38.5 & 30.3 & 12.0 & (1.6)a \\ \hline Overall average & 20.7 & 36.9 & 27.6 & 12.4 & 2.9 \\ \hline Standard deviation & 3.0 & 1.2 & 3.6 & 1.1 & 0.8 \\ \hline Mouse & 9.7 & 40.3 & 35.5 & 14.2 & 0.2 \\ \hline Opossum & 49.2 & 37.9 & 10.0 & 2.3 \\ \hline Platypus & --- & 14.5 & 71.8 & 15.1 & 0.14 \\ \hline Zebrafish & 75.7 & 23.3 & --- & --- & --- \\ \hline Medaka & --- & 71.0 & 23.7 & --- & --- \\ \hline Stickleback & --- & --- & 77.5 & 21.0 & --- \\ \hline Pufferfish & --- & --- & 55.3 & 37.8 & --- \\ \hline \multicolumn{6}{\|l\|}{Average GC} \\ \hline Human & 36.0 & 38.9 & 43.1 & 48.7 & 54.5 \\ \hline Chimp & 36.0 & 38.9 & 43.2 & 48.6 & 55.0 \\ \hline Dog & 35.9 & 38.9 & 43.2 & 48.7 & 55.8 \\ \hline Mouse(b) & 36.5 & 39.4 & 43.6 & 48.1 & 54.4 \\ \hline Platypus & --- & 40.0 & 42.9 & 47.9 & 54.9 \\ \hline Opossum & 36.0 & 38.5 & 42.9 & 48.6 & 55.6 \\ \hline Chicken & 36.6 & 39.3 & 43.4 & 48.8 & 54.7 \\ \hline Zebrafish & 36.0 & 38.2 & --- & --- & --- \\ \hline Medaka & --- & 39.9 & 42.3 & --- & --- \\ \hline Stickleback & --- & --- & 44.2 & 47.3 & --- \\ \hline Pufferfish & --- & --- & 44.4 & 48.2 & 54.7 \\ \hline Overall average & 36.2 & 39.1 & 43.3 & 48.3 & 54.8 \\ \hline Standard deviation & 0.3 & 0.6 & 0.7 & 0.5 & 0.5 \\ \hline \multicolumn{6}{\|l\|}{Average size (Mb)} \\ \hline Human & 0.90 & 0.90 & 0.80 & 0.70 & 0.70 \\ \hline Chimp & (1.4)b & 0.80 & 0.60 & 0.70 & 0.60 \\ \hline Dog & 1.02 & 0.69 & 0.53 & 0.55 & 0.59 \\ \hline Mouse & 1.09 & 1.40 & 0.99 & 0.97 & 0.30 \\ \hline Opossum & (1.6)b & 0.80 & 0.60 & 0.50 & 0.40 \\ \hline Platypus & --- & 0.90 & 1.10 & 0.50 & --- \\ \hline Chicken & 0.70 & 0.81 & 0.60 & 0.55 & (0.34)(a) \\ \hline Zebrafish & (1.9)b & 0.60 & --- & --- & --- \\ \hline Medaka & --- & (2.8)b & 0.90 & --- & --- \\ \hline Stickleback & --- & --- & (2.1)b & 0.70 & --- \\ \hline Pufferfish & --- & --- & 0.90 & 0.70 & --- \\ \hline \end{tabular}} \end{table}	PMC2678159_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline \textbf{Chemicals} & \textbf{Dm without synergists} & \textbf{Dm with PBO} & \textbf{Dm with DEF} \\ \hline propoxur & 1.97 (1.78–2.19) & 0.27 (0.17–0.42) & 1.01 (0.83–1.24) \\ \hline DEET & 1189 (1088–1299) & 611 (596–629) & 1078 (1005–1155) \\ \hline mixture & 319 (296–343) & 406 (385–428) & 128 (119–136) \\ \hline mixture ratio P:D & 1:600 & 1:2000 & 1:1000 \\ \hline \multicolumn{4}{\|l\|}{Slope of the regression lines ($\pm$ s.e.)} \\ \hline propoxur & 2.83 (0.19) & 2.16 (0.18) & 1.95 (0.22) \\ \hline DEET & 4.16 (0.42) & 3.98 (0.12) & 3.18 (0.20) \\ \hline mixture & 3.32 (0.18) & 3.76 (0.20) & 2.96 (0.14) \\ \hline \end{tabular}} \end{table}	PMC2680852_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline & \textbf{Cases (n = 547) (\%)} & \textbf{Controls (n = 544) (\%)} & \textbf{ORb (95\% CI)} \\ \hline \multicolumn{4}{\|l\|}{Menopausal status} \\ \hline Premenopausal & 187 (34.2) & 230 (42.3) & 1.0 \\ \hline Postmenopausal & 360 (65.8) & 314 (57.7) & 0.75 (0.44–1.29) \\ \hline \multicolumn{4}{\|l\|}{Age at menarche} \\ \hline $<$13 & 99 (18.1) & 87 (16.0) & 1.0 \\ \hline 13–14 & 230 (42.0) & 212 (39.0) & 0.73 (0.54–1.06) \\ \hline $\geq$ 15 & 218 (39.9) & 245 (45.0) & 0.91 (0.62–1.26) \\ \hline \multicolumn{4}{\|l\|}{Age at FFTP} \\ \hline Nulliparous & 116 (21.2) & 65 (11.9) & 1.0 \\ \hline $\leq$ 25 & 269 (49.2) & 296 (54.4) & 0.76 (0.52–1.09) \\ \hline 26–30 & 107 (19.6) & 138 (25.4) & 0.44 (0.30–0.65) \\ \hline $\geq$ 31 & 55 (10.0) & 45 (8.3) & 0.67 (0.38–1.12) \\ \hline \multicolumn{4}{\|l\|}{Number of full-term pregnancies} \\ \hline Nulliparous & 116 (21.2) & 65 (12.0) & 1.0 \\ \hline 1 & 77 (14.1) & 72 (13.2) & 0.60 (0.37–0.95) \\ \hline 2 & 160 (29.2) & 204 (37.5) & 0.45 (0.32–0.63)* \\ \hline 3+ & 194 (35.5) & 203 (37.3) & 0.55 (0.38–0.77)* \\ \hline \multicolumn{4}{\|l\|}{Use of oral contraceptives} \\ \hline Never & 359 (65.6) & 275 (50.6) & 1.0 \\ \hline Ever & 188 (34.4) & 269 (49.4) & 0.55 (0.40–0.71) \\ \hline \multicolumn{4}{\|l\|}{Postmenopausal use of estrogen} \\ \hline Never & 254 (70.6) & 208 (66.2) & 1.0 \\ \hline Ever & 106 (29.4) & 106 (33.8) & 0.80 (0.60–1.02) \\ \hline \multicolumn{4}{\|l\|}{WHR} \\ \hline $\leq$ 0.91 & 216 (39.5) & 270 (49.6) & 1.0 \\ \hline $>$ 0.91 & 331 (60.5) & 274 (50.4) & 1.49 (1.17–1.91) \\ \hline \multicolumn{4}{\|l\|}{BMI (kg/m2)} \\ \hline $\leq$ 25.4 & 243 (44.4) & 271 (49.8) & 1.0 \\ \hline $>$ 25.4 & 304 (55.6) & 273 (50.2) & 1.21 (0.96–1.55) \\ \hline \multicolumn{4}{\|l\|}{First-degree family history of breast cancer} \\ \hline No & 485 (88.7) & 519 (95.4) & 1.0 \\ \hline Yes & 62 (11.3) & 25 (4.6) & 2.63 (1.60–4.40)** \\ \hline \multicolumn{4}{\|l\|}{History of benign breast disease} \\ \hline No & 340 (62.2) & 375 (68.9) & 1.0 \\ \hline Yes & 207 (37.8) & 169 (31.1) & 1.32 (1.02–1.72)* \\ \hline \multicolumn{4}{\|l\|}{Educationa} \\ \hline Low & 332 (60.7) & 313 (57.5) & 1.0 \\ \hline Medium & 144 (26.3) & 153 (28.1) & 0.87 (0.66–1.15) \\ \hline High & 71 (13.0) & 78 (14.4) & 0.83 (0.57–1.25) \\ \hline \multicolumn{4}{\|l\|}{Current alcohol intake} \\ \hline Never & 309 (56.5) & 272 (50.0) & 1.0 \\ \hline Once a month or less & 153 (28.0) & 172 (31.6) & 0.76 (0.57–1.03) \\ \hline Daily-weekly & 85 (15.5) & 100 (18.4) & 0.74 (0.51–1.04) \\ \hline \multicolumn{4}{\|l\|}{Smoking habits} \\ \hline Nonsmokersc & 415 (75.9) & 396 (72.8) & 1.0 \\ \hline Ex-smokersd & 59 (10.8) & 76 (14.0) & 0.72 (0.49–1.07) \\ \hline Current smokerse & 73 (13.3) & 72 (13.2) & 0.95 (0.66–1.38) \\ \hline \end{tabular}} \end{table}	PMC2680904_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline \textbf{PON1 Premenopausal Postmenopausal Controls, Cases Controls, Cases Q192R Local, OR Advanced, OR Local, OR Advanced, OR by by (95\% (95\% (95\% (95\% n n stage stage n n (\%) (\%) (\%) (\%) CI)a CI)a CI)a CI)a n n (\%) (\%)} & \textbf{128 144 196 221 70 65 QQ (63.6) 1.0 (84.4) 1.0 1.0 1.0 (62.6) (62.4) (96.9) (96.9)} & \textbf{0.96 0.42 0.06 0.04 64 30 11 88 (0.55–1.60) (0.23–0.86) 6 (0.01–0.12) 3 (0.01–0.16) QR (27.8) (27.3) (14.3) (28.0) (2.6) (2.3)} & \textbf{0.94 0.04 0.02 0.23 22 10 30 1 (0.32–2.17)b (0.06–0.85)c (0.00–0.23)d (0.00–0.25)e 1 1 (0.50) RR (1.3) (0.8) (9.6) (9.1) (9.6)} & \textbf{0.95 0.33 0.05 0.05 QR 118 86 40 12 (0.60–1.62) (0.14–0.60) 7 (0.00–0.10) 4 (0.01–0.11) and (37.4) (36.4) (15.6) (3.1) (3.1) (37.6) RR} \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline PON1 L55M & LL & LM & MM & LM and MM \\ \hline \multicolumn{5}{\|l\|}{Premenopausal} \\ \hline Controls, n (\%) & 78 (33.9) & 70 (30.4) & 82 (35.7) & 152 (66.1) \\ \hline \multicolumn{5}{\|l\|}{Cases by stage} \\ \hline Local, n (\%) & 16 (14.6) & 25 (22.7) & 69 (62.7) & 94 (85.4) \\ \hline OR (95\% CI)a & 1.0 & 1.71 (0.78–2.99) & 4.12 (2.13–7.98)f & 3.05 (1.63–5.78) \\ \hline Advanced, n (\%) & 14 (18.2) & 8 (10.4) & 55 (71.4) & 63 (81.8) \\ \hline OR (95\% CI)a & 1.0 & 0.62 (0.22–1.70) & 3.71 (1.80–7.53)g & 2.28 (1.12–4.49) \\ \hline \multicolumn{5}{\|l\|}{Postmenopausal} \\ \hline Controls, n (\%) & 110 (35.0) & 55 (17.5) & 149 (47.5) & 204 (65.0) \\ \hline \multicolumn{5}{\|l\|}{Cases by stage} \\ \hline Local, n (\%) & 49 (21.5) & 52 (22.8) & 127 (55.7) & 179 (78.5) \\ \hline OR (95\% CI)a & 1.0 & 2.15 (1.28–3.75) & 1.94 (1.26–2.98)h & 1.88 (1.20–2.59) \\ \hline Advanced, n (\%) & 28 (21.2) & 30 (22.7) & 74 (56.1) & 104 (78.8) \\ \hline OR (95\% CI)a & 1.0 & 2.16 (1.15–4.22) & 1.98 (1.19–3.36)i & 2.00 (1.18–3.29) \\ \hline \end{tabular}} \end{table}	PMC2680904_table_6
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline & \textbf{All patients (n)} & \textbf{Group I (n)} & \textbf{Group II (n)} \\ \hline Total no of patients & 50 & 30 & 20 \\ \hline Cerebral Palsy & 18 & 11 & 7 \\ \hline Duchenne muscular dystrophy & 18 & 12 & 6 \\ \hline Spinal muscular atrophy & 8 & 3 & 5 \\ \hline Others & 6 & 4 & 2 \\ \hline Thoracic curves & 9 & 6 & 3 \\ \hline Thoraco-lumbar curves & 30 & 19 & 11 \\ \hline Lumbar curves & 11 & 5 & 6 \\ \hline Average age (years $\pm$ SD) & 18.1 $\pm$ 8.2 & 15.9 $\pm$ 6.5 & 24.5 $\pm$ 8.5 \\ \hline Average Follow-up (months $\pm$ SD) & 24.9 $\pm$ 8.8 & 25.3 $\pm$ 9.1 & 23.6 $\pm$ 9.1 \\ \hline Average Cobb angle (degree $\pm$ SD) & 79.3 $\pm$ 30.3 & 58.1 $\pm$ 15.2 & 109.9 $\pm$ 17.7 \\ \hline Average pelvic obliquity (degree $\pm$ SD) & 14.6 $\pm$ 9.4 & 11.7 $\pm$ 8.2 & 18.7 $\pm$ 9.8 \\ \hline Average flexibility (\%) & 29.7 $\pm$ 14.7 & 36.4 $\pm$ 14.2 & 19.9 $\pm$ 9 \\ \hline \end{tabular}} \end{table}	PMC2685769_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|} \hline \textbf{Profiles} & \textbf{Characterization of the cluster defining the profile} \\ \hline Professional & contacts at work have highest median as compared to other locations: m11 = max {m1i:i = 1,…,6} \\ \hline School & contacts at school have highest median m22 = max {m2i:i = 1,…,6} \\ \hline Leisure & contacts during leisure activities have highest median: m33 = max {m3i:i = 1,…,6} \\ \hline Big home & contacts at home have highest median: m44 = max {m4i:i = 1,…,6} \\ \hline Other place & contacts in ‘‘other place’’ have highest median: m55 = max {m5i:i = 1,…,6} \\ \hline Mixed & contacts in more than one location have a median higher than the remaining cluster: m6i.m7i for at least two i = 1,…,6. \\ \hline Low contacts & The remaining cluster \\ \hline \end{tabular}} \end{table}	PMC2691957_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline \textbf{Effect} & \textbf{Pillai(df)} & \textbf{Approximate F(df)} & \textbf{P-value} \\ \hline Age & 0.99(1) & 48.28 (25,9) & ,0.0001 \\ \hline Experience & 0.76(1) & 1.17 (25,9) & 0.43 \\ \hline Age*Experience & 0.87(1) & 2.46(25,9) & 0.08 \\ \hline \end{tabular}} \end{table}	PMC2702002_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|l\|} \hline & \multicolumn{7}{\|l\|}{\textbf{UCP2 Genotype}} \\ \hline & \textbf{n} & \textbf{AA} & \textbf{n} & \textbf{GA} & \textbf{n} & \textbf{GG} & \textbf{p} \\ \hline Gender (M/F) & 140 & 102/38(72.9\%M) & 410 & 309/101(75.4\%M) & 351 & 292/59 (83.2\%M) & 0.009 \\ \hline Age (years)* & 140 & 61.5 $\pm$ 0.94 & 410 & 62.0 $\pm$ 0.49 & 350 & 62.7 $\pm$ 057 & 0.404 \\ \hline BMI* (kgm-2) & 92 & 27.2 $\pm$ 0.51 & 285 & 26.9 $\pm$ 0.25 & 239 & 26.4 $\pm$ 0.25 & 0.174 \\ \hline LVEF & 113 & 47.2 $\pm$ 1.00 & 348 & 48.0 $\pm$ 0.64 & 288 & 47.9 $\pm$ 0.72 & 0.822 \\ \hline Predischarge Mean arterial pressure (mmHg) & 133 & 82.9 $\pm$ 0.87 & 397 & 83.2 $\pm$ 0.55 & 341 & 84.6 $\pm$ 0.61 & 0.145 \\ \hline Predischarge Systolic Blood pressure (mmHg) & 133 & 117 $\pm$ 1.28 & 397 & 116 $\pm$ 0.81 & 341 & 118 $\pm$ 0.90 & 0.163 \\ \hline Predischarge Diastolic Blood pressure (mmHg)(mmHg) & 133 & 65.9 $\pm$ 0.82 & 397 & 66.8 $\pm$ 0.54 & 341 & 67.8 $\pm$ 0.57 & 0.176 \\ \hline \multicolumn{8}{\|l\|}{History} \\ \hline Previous myocardial infarction* & 127 & 24(18.9\%) & 389 & 72 (18.5\%) & 334 & 58 (17.4\%) & 0.896 \\ \hline hypertension * & 129 & 47(36.4\%) & 400 & 157 (39.3\%) & 342 & 131 (38.3\%) & 0.847 \\ \hline Type 2 Diabetes* & 139 & 22(15.8\%) & 409 & 48(11.7\%) & 349 & 38 (10.9\%) & 0.308 \\ \hline Predischarge Fibrillation* Atrial Fibrillation* & 112 & 12(10.7\%) & 346 & 35 (10.1\%) & 297 & 47 (15.8\%) & 0.076 \\ \hline Predischarge Ventricular Fibrillation* Fibrillation* & 113 & 11(9.7\%) & 355 & 40 11.3\%) & 300 & 21 (7.0\%) & 0.173 \\ \hline \multicolumn{8}{\|l\|}{Laboratory Data} \\ \hline Total Cholesterol* (mmol/l) & 130 & 5.94 $\pm$ 0.10 & 376 & 5.95 $\pm$ 0.065 & 330 & 5.81 $\pm$ 0.068 & 0.325 \\ \hline HDL Cholesterol* (mmol/l) & 129 & 1.16 $\pm$ 0.026 & 371 & 1.16 $\pm$ 0.017 & 325 & 1.15 $\pm$ 0.018 & 0.913 \\ \hline LDL Cholesterol* (mmol/l) & 97 & 3.96 $\pm$ 0.10 & 299 & 3.98 $\pm$ 0.058 & 268 & 3.83 $\pm$ 0.069 & 0.225 \\ \hline Triglycerides* (mmol/l) & 130 & 2.02 $\pm$ 0.11 & 376 & 2.08 $\pm$ 0.096 & 330 & 2.01 $\pm$ 0.069 & 0.791 \\ \hline Plasma Creatinine† ($\mu$mol/l) & 136 & 83 (79–87) & 405 & 85 (82–87) & 347 & 85 (83–87) & 0.600 \\ \hline Creatinine Clearance* (ml/s) & 99 & 1.28 $\pm$ 0.047 & 308 & 1.28 $\pm$ 0.023 & 267 & 1.32 $\pm$ 0.028 & 0.546 \\ \hline Peak Creatine kinase† (units/l) & 105 & 1440(1250–1660) & 327 & 1610(1480–1740) & 269 & 1640(1510–1680) & 0.304 \\ \hline Plasma Glucose (mmol/l) & 137 & 8.55 $\pm$ 0.27 & 404 & 8.64 $\pm$ 0.15 & 344 & 8.55 $\pm$ 0.16 & 0.912 \\ \hline Glycated Hemoglobin \% & 105 & 6.07 $\pm$ 0.11 & 324 & 6.06 $\pm$ 0.06 & 274 & 6.03 $\pm$ 0.06 & 0.905 \\ \hline \multicolumn{8}{\|l\|}{Discharge Medications} \\ \hline ACE inhibitor * & 122 & 36(29.5\%) & 374 & 121 (32.4\%) & 318 & 109 (34.3\%) & 0.624 \\ \hline $\beta$-blocker * & 122 & 78(63.9\%) & 374 & 232 (62.0\%) & 318 & 176 (55.3\%) & 0.119 \\ \hline \multicolumn{8}{\|l\|}{Neurohormonal Data} \\ \hline ANP (pmol/l)‡ & 138 & 26.8(24.4–29.4) & 403 & 28.5(27.0–30.0) & 346 & 28.8(27.1–30.6) & 0.406 \\ \hline BNP (pmol/l)‡ & 138 & 18.2(16.4–20.2) & 404 & 19.8(18.7–21.0) & 346 & 19.9(18.8–21.1) & 0.290 \\ \hline NTproBNP (pmol/l)‡ & 137 & 98.6(87.0–112) & 399 & 112(104–121) & 344 & 111(103–121) & 0.200 \\ \hline Endothelin-1 (pmol/l)‡ & 137 & 1.64(1.52–1.77) & 398 & 1.80(1.73–1.88) & 340 & 1.76(1.167–1.81) & 0.110 \\ \hline \end{tabular}} \end{table}	PMC2702310_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline & \textbf{Physicians (n = 900)} & \textbf{Nurses (n = 277)} \\ \hline Percent (regularly, that occasionally, use dietary or supplements seasonally) & 72\% & 89\% \\ \hline Percent supplements regular users of dietary & 51\% & 59\% \\ \hline Recommend to patients dietary supplements & 79\% & 82\% \\ \hline \end{tabular}} \end{table}	PMC2714854_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline \textbf{Study} & \textbf{Outcome} & \textbf{Parameter interval estimate and 95\% confidence} \\ \hline \multicolumn{3}{\|l\|}{Mortality 2° to COPD} \\ \hline Ishida W, et al., Japan, 2007 [23] & Decreased mortality 2° to COPD in statin users & Inverse dispensed prefecture, correlation and p $<$ mortality 0.0001 between due statin COPD prescriptions by \\ \hline \multicolumn{3}{\|l\|}{Respiratory-related urgent care} \\ \hline Keddissi JI, et al., USA, 2007 [26] & Reduction department-visits statin users in respiratory-related and/or hospitalizations emergency- in & Incidence obstructive patient-yrs patient-yrs of in in spirometry respiratory statin control, users p group = related versus 0.02 0.12 urgent 0.19 $\pm$ 0.29/ $\pm$ care, 0.32/ \\ \hline \multicolumn{3}{\|l\|}{Lung function} \\ \hline Keddissi JI, et al., USA, 2007 [26] & Lower users decline in FEV1 and FVC/yr in statin & Obstructive change change (p change change (p $<$ $<$ 0.0001) 0.0001) in in in in FEV1 FEV1–86 FVC FVC-150 spirometry +33 +5 $\pm$ $\pm$ $\pm$ $\pm$ 207 168 452 328 group ml/yr ml/yr ml/yr ml/yr in in in in statin control control statin users users \\ \hline Lee T-M, et al., Taiwan, 2008 [19] & No in statin difference users in pulmonary function parameters & Pravastatin follow-up Placebo follow-up group: 55 55 group: $\pm$ $\pm$ 19 14, FEV1\% FEV1\% p $>$ at 0.05 baseline at baseline 56 51 $\pm$ 13, $\pm$ 18, at at \\ \hline \multicolumn{3}{\|l\|}{Exercise capacity} \\ \hline Lee T-M, et al., Taiwan, 2008 [19] & Improvement in exercise time in statin users & Pravastatin 599 Placebo $\pm$ 273, $\pm$ 323, at group: follow-up at group: follow-up exercise exercise 609 922 $\pm$ time 180, time $\pm$ in 328 p s in $<$ at s 0.05 baseline at baseline 608 \\ \hline \multicolumn{3}{\|l\|}{Borg dyspnea score after exercise tests} \\ \hline Lee T-M, et al., Taiwan, 2008 [19] & Lesser users degree of dyspnea after exercise in statin & Pravastatin baseline Placebo 6.9 $\pm$ 0.8, group: 7.0 at group: $\pm$ follow-up 0.8, Borg Borg at dyspnea follow-up 6.9 dyspnea $\pm$ 1.0, score 4.0 score p $<$ $\pm$ at 0.05 0.7 baseline at \\ \hline \multicolumn{3}{\|l\|}{CRP/IL-6 levels} \\ \hline Lee T-M, et al., Taiwan, 2008 [19] & Decrease in CRP/IL-6 levels in statin users & Pravastatin 3.54, Placebo 2.67, at at follow-up follow-up group: group: CRP 3.85 2.66 CRP (mg/l) $\pm$ $\pm$ (mg/l) 2.56 2.49, at baseline at p $<$ baseline 0.05 4.06 3.94 $\pm$ $\pm$ \\ \hline \end{tabular}} \end{table}	PMC2716302_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|} \hline Age (years) & 62 $\pm$ 18 (19 to 100) \\ \hline Female/male & 83/97 \\ \hline SAPS II & 37 $\pm$ 18 (9 to 103) \\ \hline Mortality & 19\% (35 out of 180 patients) \\ \hline Cirrhosis & 6 \\ \hline Cancer & 45 \\ \hline Community-acquired/postoperative peritonitis & 112/68 \\ \hline \end{tabular}} \end{table}	PMC2717471_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline & \multicolumn{2}{\|l\|}{\textbf{Known}} & \multicolumn{2}{\|l\|}{\textbf{Unknown}} \\ \hline \textbf{Category*} & \textbf{Duplicated} & \textbf{Retrotransposed} & \textbf{Single-exon pseudogene} & \textbf{Multi-exon pseudogne} \\ \hline Unsupported & 507 & 162 & 453 & 69 \\ \hline Long UTR & 62 & 11 & 25 & 6 \\ \hline Short CDS & 1 & 0 & 4 & 0 \\ \hline Poly-A tail & 9 & 2 & 16 & 3 \\ \hline Segmentally duplicated & 36 & 2 & 1 & 1 \\ \hline Single-exon singletons & 39 & 34 & 115 & 14 \\ \hline Total (non redundant) & 627 & 189 & 539 & 84 \\ \hline \end{tabular}} \end{table}	PMC2724416_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline & \textbf{Fibromyalgia} & \textbf{RA/SLE} & \textbf{Major depressiona} & \textbf{Healthy controls} \\ \hline Number analyzed & 202 & 51 & 11 & 213 \\ \hline Age, years & 51 $\pm$ 10.5 & 49 $\pm$ 13.1a & 46 $\pm$ 11.4b & 43 $\pm$ 14.0c \\ \hline Gender ratio, female/male & 16/1 & ND & 5 $\pm$ 1 & 13 $\pm$ 1 \\ \hline Number of pain locations & 16 $\pm$ 4.9 & 7.0 $\pm$ 4.4 & 4.0 $\pm$ 2.5 & 1.6 $\pm$ 2.3 \\ \hline \end{tabular}} \end{table}	PMC2745803_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline & \textbf{Diana-microT} & \textbf{PicTar} & \textbf{TargetScan 4.2} \\ \hline Diana-microT & 22391 & 8882 & 10651 \\ \hline PicTar & & 17135 & 12902 \\ \hline TargetScan 4.2 & & & 19299 \\ \hline \end{tabular}} \end{table}	PMC2752464_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline \textbf{Treatment Comparison} & \multicolumn{2}{\|l\|}{\textbf{Mixed Treatment Comparison}} & \multicolumn{2}{\|l\|}{\textbf{Adjusted Indirect Comparison}} \\ \hline & \textbf{Odds Ratio} & \textbf{95\% Credible Interval} & \textbf{Odds Ratio} & \textbf{95\% Confidence Interval} \\ \hline Fluconazole vs. Control & 0.81 & (0.48, 1.37) & 0.94 & (0.54, 1.63) \\ \hline Itraconazole vs. Control & 0.90 & (0.41, 1.99) & 0.49 & (0.15, 1.56) \\ \hline Liposomal Amphotericin B vs. Control & 0.50 & (0.09, 2.33) & 0.54 & (0.10, 2.52) \\ \hline Ketoconazole vs. Control & 1.83 & (0.38, 8.93) & 1.66 & (0.41, 6.66) \\ \hline Intraconazole vs. Fluconazole & 1.12 & (0.52, 2.41) & 1.69 & (0.58, 5.33) \\ \hline Liposomal Amphotericin B vs. Fluconazole & 0.62 & (0.10, 3.17) & 0.57 & (0.09, 3.39) \\ \hline Ketoconazole vs. Fluconazole & 2.27 & (0.43, 12.09) & 1.76 & (0.39, 7.94)* \\ \hline Liposomal Amphotericin B vs. Itraconazole & 0.55 & (0.09, 3.11) & 1.10 & (0.14, 8.65), * \\ \hline Ketoconazole vs. Itraconazole & 2.03 & (0.35, 11.87) & 3.38 & (0.54, 21.16)* \\ \hline Ketoconazole vs. Liposomal Amphotericine B & 3.68 & (0.41, 35.30) & 3.07 & (0.34, 27.48)*** \\ \hline \end{tabular}} \end{table}	PMC2760541_table_4
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Rs10954213} & \multicolumn{2}{\|l\|}{\textbf{Allele}} & \multicolumn{3}{\|l\|}{\textbf{Genotype}} \\ \hline \textbf{Group} & \textbf{A} & \textbf{G} & \textbf{AA} & \textbf{AG} & \textbf{GG} \\ \hline BPD & 129 & 153 & 33 & 63 & 45 \\ \hline C & 183 & 197 & 44 & 95 & 51 \\ \hline MDD & 8 & 6 & 1 & 6 & 0 \\ \hline SZ & 100 & 96 & 25 & 50 & 23 \\ \hline \end{tabular}} \end{table}	PMC2760574_table_5
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline \textbf{Genome/$\Delta$ bit score to 2nd hit1} & \textbf{R2} & \textbf{P} & \textbf{$\Delta$ $\sigma$ Heterokont} & \textbf{$\Delta$ $\sigma$ Reds} \\ \hline P. ramorum/5\% & 0.714 & 0.007 & 2.71 & -0.12 \\ \hline P. sojae/5\% & 0.717 & 0.007 & 2.67 & -0.15 \\ \hline P. ramorum/10\% & 0.629 & 0.019 & 2.75 & -0.16 \\ \hline P. sojae/10\% & 0.644 & 0.016 & 2.72 & -0.18 \\ \hline \end{tabular}} \end{table}	PMC2770532_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|l\|} \hline & \multicolumn{2}{\|l\|}{\textbf{Mean Amplitude (mV) (300–800 ms)}} & \multicolumn{2}{\|l\|}{\textbf{Peak Amplitude (mV) (jackknifed values)}} & \multicolumn{2}{\|l\|}{\textbf{Peak Latency (ms) (jackknifed values)}} \\ \hline \textbf{Condition} & \textbf{M} & \textbf{SE} & \textbf{M} & \textbf{SE} & \textbf{M} & \textbf{SE} \\ \hline Target Present Search & 21.33 & 0.40 & 22.20 & 0.06 & 704 & 0.5 \\ \hline Target Absent Search & 21.15 & 0.25 & 21.90 & 0.03 & 680 & 0.6 \\ \hline Change Detection & 21.43 & 0.32 & 21.96 & 0.05 & 536 & 9.4 \\ \hline \end{tabular}} \end{table}	PMC2777337_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline \textbf{PCT test} & \textbf{Cutoff 0.5 ng /mL} & \textbf{Cutoff 2.0 ng/mL} & \textbf{Cutoff 10 ng/mL} \\ \hline Sensitivity & 0.52 [0.37–0.67] & 0.20 [0.10–0.34] & 0.02 [0.00–0.13] \\ \hline Specificity & 0.76 [0.66–0.83] & 0.91 [0.84–0.95] & 0.97 [0.92–0.99] \\ \hline Positive predictive value & 0.47 [0.33–0.61] & 0.47 [0.25–0.71] & 0.25 [0.01–0.78] \\ \hline Negative predictive value & 0.79 [0.70–0.86] & 0.73 [0.65–0.80] & 0.71 [0.63–0.78] \\ \hline \end{tabular}} \end{table}	PMC2792948_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline & \textbf{Perceived Factor susceptibility 1} & \textbf{Perceived Factor severity 2} \\ \hline \\ \hline Adolescent alcohol use outside home & 0.834 & 0.182 \\ \hline Worries about adolescent alcohol use & 0.843 & 0.104 \\ \hline Approved age for alcohol use & 0.085 & 0.657 \\ \hline Adolescents have been offered alcohol at home & -0.165 & -0.731 \\ \hline Parents' opinion about adolescents' alcohol use & -0.112 & -0.714 \\ \hline \end{tabular}} \end{table}	PMC2809065_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline \textbf{Parameter} & \textbf{Coefficient} & \textbf{Standard error} & \textbf{95\% Wald CI} & \textbf{P value} \\ \hline (Intercept) & 6.816 & 0.0386 & 6.740 - 6.891 & $<$ 0.001 \\ \hline Year 2009 & -3.907 & 0.2034 & -4.306 - -3.508 & $<$ 0.001 \\ \hline Year 2008 & -4.405 & 0.2598 & -4.914 - -3.895 & $<$ 0.001 \\ \hline Year 2007 & -3.085 & 0.1365 & -3.353 - -2.818 & $<$ 0.001 \\ \hline Year 2006 & -2.721 & 0.1149 & -2.946 - -2.496 & $<$ 0.001 \\ \hline Year 2005 & -0.948 & 0.0540 & -1.054 - -0.842 & $<$ 0.001 \\ \hline Year 2004 & -0.483 & 0.0462 & -0.574 - -0.393 & $<$ 0.001 \\ \hline Year 2003 & 0 a \\ \hline Pregnancy & -2.530 & 0.1196 & -2.765 - -2.296 & $<$ 0.001 \\ \hline $\geqq$ 5 years old & 0.532 & 0.0409 & 0.452 - 0.612 & $<$ 0.001 \\ \hline $<$5 years old & 0 a \\ \hline (Scale) & 2.068 b \\ \hline \end{tabular}} \end{table}	PMC2823607_table_3
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline & \textbf{Isolated (n = 103) nurses} & \textbf{Non-isolated (n = 94) nurses} & \textbf{p value} \\ \hline \multicolumn{4}{\|l\|}{Age categories (years)} \\ \hline 20 - 39 & 18 (17.5) & 24 (26.1) & Chi-square test for trend = 0.176, df = 1, p = 0.675. \\ \hline 40 - 49 & 57 (55.3) & 39 (42.4) \\ \hline 50 and above & 28 (27.2) & 29 (31.5) \\ \hline \multicolumn{4}{\|l\|}{Grade} \\ \hline D, E or F & 7 (7.1) & 8 (8.7) & Chi-square test for trend = 2.350, df = 1, p = 0.125. \\ \hline G & 79 (80.6) & 61 (66.3) \\ \hline H & 12 (12.2) & 23 (25.0) \\ \hline \multicolumn{4}{\|l\|}{Practice list size} \\ \hline Up to 2000 patients & 12 (12.1) & 5 (5.6) & Chi-square test for trend = 5.107, df = 1, p = 0.024. \\ \hline 2001 - 4000 & 30 (30.3) & 18 (20.2) \\ \hline 4001 - 6000 & 24 (24.2) & 29 (32.6) \\ \hline 6001 - 8000 & 15 (15.2) & 12 (13.5) \\ \hline 8001 - 10,000 & 12 (12.1) & 14 (15.7) \\ \hline Over 10,000 patients & 6 (6.1) & 11 (12.4) \\ \hline \multicolumn{4}{\|l\|}{Number of practice nurses in the team} \\ \hline 1 & 40 (38.8) & 21 (22.8) & Chi-square test for trend = 8.847, df = 1, p = 0.003. \\ \hline 2 & 44 (42.7) & 39 (42.4) \\ \hline 3 or more & 19 (18.4) & 32 (34.8) \\ \hline \end{tabular}} \end{table}	PMC2823612_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline \textbf{Time [days]◆:} & & \textbf{0} & \textbf{28} & \textbf{35} \\ \hline Treatment group & Animal \\ \hline Vaccinated & V1 & 0.057* & 0.185 & 0.736 \\ \hline & V2 & 0.056 & 0.267 & 0.476 \\ \hline & V3 & 0.054 & & 0.223 \\ \hline & V4 & 0.051 & 0.121 & 0.542 \\ \hline & V5 & 0.052 & 0.054 & 0.408 \\ \hline & Average\# & 0.054a & 0.157a & 0.477a \\ \hline Unvaccinated & C1 & 0.055 & 0.059 & 0.099 \\ \hline & C2 & 0.052 & 0.060 & 0.214 \\ \hline & C3 & 0.056 & 0.055 & 0.106 \\ \hline & C4 & 0.057 & 0.060 & 0.067 \\ \hline & Average & 0.055a & 0.059a & 0.121b \\ \hline \end{tabular}} \end{table}	PMC2824702_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline & \textbf{IL-2} & \textbf{IL-2+ART} & \textbf{Control} & \textbf{Total} \\ \hline \multicolumn{5}{\|l\|}{Age (years)} \\ \hline Median & 35 & 35 & 36 & 36 \\ \hline Interquartile range & & & & 30–44 \\ \hline Gender (\% female) & 19.1 & 14.9 & 17.6 & 17.2 \\ \hline \multicolumn{5}{\|l\|}{Race (\%)} \\ \hline Asian & 24.7 & 26.4 & 24.2 & 25.1 \\ \hline Black & 4.5 & 4.6 & 8.8 & 6.0 \\ \hline White/other & 70.8 & 69.0 & 67.0 & 68.9 \\ \hline \multicolumn{5}{\|l\|}{CD4+ count (cells/mm3)} \\ \hline Median & 399 & 425 & 432 & 419 \\ \hline Interquartile range & & & & 359–512 \\ \hline \multicolumn{5}{\|l\|}{HIV-RNA (copies)} \\ \hline Median & 23,508 & 21,881 & 24,328 & 22,384 \\ \hline Interquartile range & & & & 7,189–61,169 \\ \hline \multicolumn{5}{\|l\|}{Medication Use and History} \\ \hline Antiretroviral (ART) naı¨ve (\%) & 76.4 & 87.4 & 72.5 & 78.7 \\ \hline Months since last ART use* (median) & 36.9 & 28.9 & 32.0 & 21.3 \\ \hline Current OI prophylaxis use (\%) & 3.4 & 2.3 & 2.2 & 2.6 \\ \hline \multicolumn{5}{\|l\|}{Likely mode of HIV transmission** (\%)} \\ \hline Person of same sex & 60.7 & 56.3 & 61.5 & 59.6 \\ \hline Person of opposite sex & 38.2 & 41.4 & 37.4 & 39.0 \\ \hline Injection drug use & 2.2 & 4.6 & 0.0 & 2.2 \\ \hline Blood products & 1.1 & 1.1 & 0.0 & 0.7 \\ \hline Other or unknown & 2.2 & 2.3 & 2.2 & 2.2 \\ \hline \multicolumn{5}{\|l\|}{Hepatitis Status (\%)} \\ \hline Hepatitis B surface antigen positive & 5.6 & 0.0 & 5.6 & 3.8 \\ \hline Hepatitis C antibody positive & 5.7 & 5.7 & 7.8 & 6.4 \\ \hline \multicolumn{5}{\|l\|}{BMI (kg/m2)} \\ \hline Median & 23.5 & 23.2 & 23.6 & 23.4 \\ \hline Interquartile range & & & & 21.2–26.2 \\ \hline \multicolumn{5}{\|l\|}{Total cholesterol (mg/dl)} \\ \hline Median & 166 & 170 & 170 & 170 \\ \hline Interquartile range & & & & 147–196 \\ \hline \end{tabular}} \end{table}	PMC2826395_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Gene} & \textbf{Coverage} & \textbf{\#G} & \textbf{\#A} & \textbf{Freq. of G} & \textbf{aa change} \\ \hline Gabra3 & 679 & 631 & 48 & 92.93\% & I/M \\ \hline Elavl2 & 633 & 9 & 624 & 1.422\% & I/V \\ \hline Elavl2 & 625 & 15 & 610 & 2.400\% & N/D \\ \hline Elavl4 & 443 & 4 & 439 & 0.903\% & 3' UTR \\ \hline Elavl4 & 462 & 3 & 459 & 0.649\% & 3' UTR \\ \hline Elavl4 & 220 & 2 & 218 & 0.909\% & T/A \\ \hline Matr3 & 220 & 3 & 217 & 1.364\% & R/G \\ \hline Stk22c & 209 & 2 & 207 & 0.957\% & D/G \\ \hline Ube1x & 349 & 3 & 346 & 0.860\% & I/M \\ \hline Xpo7 & 390 & 3 & 387 & 0.769\% & D/G \\ \hline Hnrph2 & 265 & 2 & 263 & 0.755\% & K/E \\ \hline \end{tabular}} \end{table}	PMC2831006_table_5
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|} \hline \textbf{E. chaffeensis protein} & \textbf{OM (Da)} & \textbf{PM (Da)} & \textbf{MS (Da)} & \textbf{Mass (OM-PM difference in Da)} & \textbf{Mass (PM-MS difference in Da)} \\ \hline Native TRP47 & ,47,000 & 32,925.5 & 33,104.5 & 14,075 & 179 \\ \hline Native TRP32 & ,32,000 & 22,449.0 & 22,736.8 & 9,550 & 288 \\ \hline GST-TRP47 & ,67,000 & 56,581.6 & 56,698.0 & 10,418 & 116 \\ \hline GST-NterTRP47 & ,42,000 & 41,580.6 & ND & 419 & ND \\ \hline GST-CterTRP47 & ,55,000 & 43,525.4 & 43,522.0 & 11,474 & 3 \\ \hline \end{tabular}} \end{table}	PMC2832021_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline & \textbf{Initial individuals) 3 months (n = 583} & & \textbf{After individuals) 3 months (n = 559} \\ \hline Variable & Unadjusted CI) Hazard Ratio (95\% & Adjusted (95\% CI) Hazard Ratio & Unadjusted CI) Hazard Ratio (95\% & Adjusted (95\% CI) Hazard Ratio \\ \hline Age (years) & 0.99 (0.95-1.04) & 0.87 (0.79-0.96) & 0.98 (0.95-1.10) & N/S \\ \hline \multicolumn{5}{\|l\|}{Sex;} \\ \hline Female & REF & & REF \\ \hline Male & 4.17 (1.83-.54) & 9.55 (2.35-38.78) & 0.59 (0.30-1.16) & 0.55 (0.27-1.10) \\ \hline Log10 RNA HIV & 1.85 (0.86-3.97) & 2.69 (1.11-6.51) & 0.83 (0.59-1.13) & N/S \\ \hline Transfer in & 0.99 (0.13-7.30) & N/S & 0.38 (0.05-2.78) & N/S \\ \hline Log10 CD4 & 1.35 (0.78-2.40) & 2.02 (0.58-4.76) & 0.83 (0.65-1.07) & 0.87(0.67-1.13) \\ \hline \multicolumn{5}{\|l\|}{Prior TB;} \\ \hline No & REF & & REF \\ \hline Yes & 1.42 (0.63-3.20) & 1.16 (0.33-4.03) & 1.77 (1.04-2.98) & 1.32 (0.73-2.38) \\ \hline \multicolumn{5}{\|l\|}{WHO stage} \\ \hline 1 or 2 & REF & & REF \\ \hline 3 or 4 & 2.33 (0.92-5.92) & N/S & 2.11 (1.15-3.87) & 1.94 (0.99-3.38) \\ \hline Unknown & 0.40 (0.05-3.32) & N/S & 1.27 (0.52-3.12) & 1.43 (0.58-3.56) \\ \hline \end{tabular}} \end{table}	PMC2835706_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|} \hline \textbf{Variable} & \textbf{No. (\%)} \\ \hline Mortality & 1 (1.7) \\ \hline Myocardial infarction & 1 (1) \\ \hline Target vessel reintervention & 4 (6) \\ \hline Reoperation for bleeding & 2 (3) \\ \hline Pleural effusion & 2 (3) \\ \hline Pulmonary infection & 2 (3) \\ \hline Post cardiotomy syndrome & 1 (1) \\ \hline \end{tabular}} \end{table}	PMC2842890_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline \textbf{Subscale} & \textbf{Patients postoperative (n = 151) 7 years} & \textbf{Reference group Postoperative (n = 65) 7 years} & \textbf{p-value} \\ \hline SF-36 PF & 54 (27.2) & 69 (31.3) & 0.01 \\ \hline SF-36 RP & 45 (44.6) & 60 (46.0) & 0.05 \\ \hline SF-36 BP & 63 (28.1) & 69 (26.9) & 0.19 \\ \hline 10 SF-36 GH & 63 (22.4) & 62 (25.0) & 0.94 \\ \hline SF-36 VT & 59 (46.4) & 72 (43.0) & 0.05 \\ \hline the SF-36 SF & 62 (23.8) & 65 (21.8) & 0.36 \\ \hline SF-36 RE & 81 (23.2) & 79 (24.7) & 0.53 \\ \hline (Fig- SF-36 MH & 79 (19.1) & 72 (43.0) & 0.90 \\ \hline the WOMAC pain & 86 (16.5) & 91 (18.2) & 0.05 \\ \hline 7-year WOMAC stiffness & 78 (22.1) & 89 (20.0) & $<$0.001 \\ \hline WOMAC function & 76 (21.1) & 73 (23.8) & 0.56 \\ \hline \end{tabular}} \end{table}	PMC2847954_table_4
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|} \hline \multicolumn{2}{\|l\|}{\textbf{(A) A DNA database.}} \\ \hline \multicolumn{2}{\|l\|}{CCCTAATG} \\ \hline \multicolumn{2}{\|l\|}{TTAATAAT} \\ \hline \multicolumn{2}{\|l\|}{ATAATGCG} \\ \hline \multicolumn{2}{\|l\|}{(B) All 5-patterns in the database.} \\ \hline \multicolumn{2}{\|l\|}{CCCTA, CCTAA, CTAAT, TAATG, TTAAT, TAATA} \\ \hline \multicolumn{2}{\|l\|}{AATAA, ATAAT, ATAAT, TAATG, AATGC, ATGCG} \\ \hline \multicolumn{2}{\|l\|}{(C) Some unique signatures in the database.} \\ \hline $\Omega$5,1 & CCCTA, CCTAA, AATAA, AATGC, ATGCG \\ \hline $\Omega$5,2 & ATGCG \\ \hline $\Omega$4,1 & CCCT, CCTA, ATGC, TGCG \\ \hline $\Omega$4,2 & TGCG \\ \hline \end{tabular}} \end{table}	PMC2848650_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|} \hline \multicolumn{3}{\|l\|}{Total number of 16-year-olds in the city of Uppsala: n = 2,465} \\ \hline \multicolumn{3}{\|l\|}{Participated in the screening procedure: n = 2,300} \\ \hline \multicolumn{3}{\|l\|}{Delivered complete screening questionnaires: n = 2,270} \\ \hline & Selected Depression Epidemiological attempted due suicide Inventory to high Studies scores (BDI) scale on or (CES) the Center Beck or for had & Selected as controls \\ \hline Selected for interview & n = 355 & n = 355 \\ \hline Interviewed by means of (structured DICA) interview & n = 314 & n = 317 \\ \hline Refused to participate in follow up & n = 6 & n = 10 \\ \hline Interviewed participate in and follow-up willing to & n = 308 & n = 307 \\ \hline Depressed at DICA interview & & n = 55 \\ \hline & Depressed having at least at screening one suicide or at attempt: interview n = or 363 & Controls interview n = 252 (not and depressed without any at suicide screening attempt): or \\ \hline Incomplete nr personal identification & n = 1 & n = 2 \\ \hline Included in follow-up & n = 362 & n = 250 \\ \hline Men/Women & 80/282 & 56/194 \\ \hline Age at follow up, years & 31.6 $\pm$ 0.7 & 31.6 $\pm$ 0.6 \\ \hline Major investigation depression Females/Males at first & 213/48 \\ \hline Dysthymia depression Females/Males and at first sub-syndromal investigation & 70/31 \\ \hline \end{tabular}} \end{table}	PMC2853351_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|} \hline \textbf{Compd} & \textbf{R1} & \textbf{R2} & \textbf{R3} & \textbf{IC50 TryR [mm]} \\ \hline 39 & Me & Me & 4’-Methylphenyl & 8.6 \\ \hline 40 & Me & CH2CH3 & Thiophen-2-yl & 12.8 \\ \hline 41 & Me & CH2CH3 & 2’-Fluoro-5’-Bromophenyl & 10.2 \\ \hline 42 & Me & H & 2’-Fluoro-5’-Bromophenyl & $>$100 \\ \hline 43 & H & H & 2’-Fluoro-5’-Bromophenyl & 92 \\ \hline 44 & Me & CH2CH3 & Pyridine-3-yl & $>$100 \\ \hline 45 & Me & CH2CH3 & 4’-Bromothiophen-2-yl & 13.0 \\ \hline 46 & Me & CH2CH3 & 4’-Trifluoromethylphenyl & 15.2 \\ \hline 47 & Me & CH2CH3 & Phenyl & 11.3 \\ \hline 48 & Me & CH2CH2NMe2 & 2’-Fluoro-5’-Bromophenyl & $>$100 \\ \hline 49 & Me & CH2CH3 & CH=CHC6H5 & 2.6 \\ \hline 50 & Me & CH(CH3)2 & 2’-Fluoro-5’-Bromophenyl & $>$50 \\ \hline 51 & Me & (CH2)3CH3 & 2’-Fluoro-5’-Bromophenyl & $>$100 \\ \hline 52 & Me & cyclopentyl & 2’-Fluoro-5’-Bromophenyl & $>$100 \\ \hline \end{tabular}} \end{table}	PMC2855869_table_2
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|} \hline & & \multicolumn{2}{\|l\|}{\textbf{TeleAtlas}} & \multicolumn{2}{\|l\|}{\textbf{ArcView/NAVTEQ}} \\ \hline \textbf{Address status} & \textbf{N} & \textbf{Error1} & \textbf{N (\%)2} & \textbf{Error1} & \textbf{N (\%)2} \\ \hline Self-reported Post-E911 Street & 71 & 132 (75, 309) & 52 (73\%) & 40 (17, 70) & 70 (99\%) \\ \hline Self-reported Pre-E911 Street & 37 & 243 (117, 418) & 34 (92\%) & 236 (153, 413) & 29 (78\%) \\ \hline Total Addresses3 & 135 & 174 (81, 357) & 86 (64\%) & 62 (25, 151) & 99 (73\%) \\ \hline \end{tabular}} \end{table}	PMC2867955_table_0
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|l\|l\|} \hline \textbf{Clinical group} & \textbf{Controls (n = 27)} & \textbf{Not (n = Infected 118)} & \textbf{Infected (n = 74)} \\ \hline & & & & Culture (n = 41) positive & Culture (n = 33) Negative \\ \hline Duration antibiotic (days) of therapy & 0 (0,0) & 2 (1,3) & 5 (5,7) & 7 (5,7) & 5 (5,7) \\ \hline sICAM-1 (ng/ml), & 165 (130,290) & 168 (140,228) & 341 (236,554) P $<$ 0.001 & 405 P $<$ 0.001 (252,666) & 306 P $<$ 0.001 (230,484) \\ \hline hsCRP(mg/l), & 0.1 (0.1,0.4) & 0.1 (0.1,0.7) & 0.85 P $<$ 0.001 (0.3,15.9) & 2.0 P $<$ (0.7,21.2) 0.001 & 0.45 P = 0.012 (0.1,2.2) \\ \hline SAA(mg/l) & 0.9 (0.9,1.0) & 1.0 (0.9,2.0) & 1.5 (0.9,5.8) P = 0.004 & 2.0 (1.0-10.0) P = 0.001 & 1.0 (0.9,2.0) P $>$ 0.05 \\ \hline sE-selectin(ng/ml) & 71 (51,118) & 90 (59,124) & 135 (94,192) P $<$ 0.001 & 158 P $<$ 0.001 (94,207) & 109 P = 0.009 (92,184) \\ \hline \end{tabular}} \end{table}	PMC2868836_table_3
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|} \hline \textbf{Theme} & \textbf{Descriptive terms (reference)} \\ \hline Methods development that support sustainable & Health sustainability. designed participatory process.54 Health impacts points government Cities development programmes in Impact Impact and time to integrated process. vulnerabilities initiatives and Use with Assessment Pathways building examples of provide sustainability Outline health such as resilience.56 of as opportunities a as of climate and provided method a response Health method sustainability appraisal change of Action of for assessing for mechanisms.55 six-stage promoting addressing approach—‘Spectrum’, hazards Zones agendas appraisal the and at health potential sustainable different Healthy with and \\ \hline Governance change and attitude/behaviour & Example water Action Links at behaviour.59 home between quality Trust.57 and of multi-disciplinary strategies based at attitudes work,58 on do recommendations are and not suggested perceptions approach necessarily for to of improving water from translate recycling the treatment World into behaviour.59 behaviour recycling Humanity and \\ \hline Gardening and Food & sourcing Food farmers schools.56 Community social, co-operatives economic to food promote gardens locally and local and could to environmental reduce community growing, act as food a improving model agriculture, policies miles.25,60 for supply at the local partnerships implementation of level.61 fruit to with of \\ \hline energy saving/Waste Management & Affordable Energy Combined Wind reduce turbines clinical saving warmth heat and equipment waste.25 and solar programme, power panels for plant heating sustainable installed.25 and energy and ventilation.60 reusable buildings.56 efficiency nappies measures.62 \\ \hline Transport & green travel plans.25,60 \\ \hline \end{tabular}} \end{table}	PMC2872568_table_1
	\begin{table} \scalebox{0.60}{ \begin{tabular}{\|l\|l\|l\|l\|} \hline & \textbf{All oligo (service) arrays} & \textbf{Oligo arrays following normal karyotype} & \textbf{Oligo arrays as first line test} \\ \hline Total patients & 2414 & 1245 & 1169 \\ \hline Abnormal patients & 585 (24\%) & 325 (26\%) & 260 (22\%) \\ \hline - inherited & 169 & 97 & 72 \\ \hline - de novo & 63 & 52 & 11 \\ \hline - unknown inheritance & 353 & 176 & 177 \\ \hline \end{tabular}} \end{table}	PMC2885406_table_2